

**ORION PHARMA LIMITED AND ITS SUBSIDIARIES**

**Consolidated Statement of Financial Position**

**As at 30 June 2020**

	Notes	Amount in Taka	
		30 June 2020	30 June 2019
<b>Assets</b>			
<b>Non-current assets</b>		<b>19,094,525,507</b>	<b>18,714,576,518</b>
Property, plant and equipment	5	14,930,942,237	12,937,529,084
Right of use Assets	6	50,347,853	-
Construction work-in-progress	7	1,651,460,156	3,369,075,037
Investment in associate	9	319,403,000	254,282,000
Other investments	10	2,142,372,262	2,153,690,397
<b>Current assets</b>		<b>17,746,581,258</b>	<b>12,275,841,589</b>
Inventories	11	1,277,620,688	918,051,609
Trade and other receivables	12	11,648,659,127	10,108,011,586
Advances, deposits and prepayments	13	3,766,540,017	1,145,562,629
Fixed deposit with banks	14	19,583,098	12,028,336
Cash and cash equivalents	15	1,034,178,328	92,187,429
<b>Total assets</b>		<b>36,841,106,765</b>	<b>30,990,418,107</b>
<b>Shareholder's equity and liabilities</b>			
<b>Shareholder's equity</b>		<b>17,963,721,397</b>	<b>17,594,351,998</b>
Share capital	16	2,340,000,000	2,340,000,000
Share premium		8,016,892,026	8,016,892,026
Reserves	17	1,936,593,119	1,908,891,010
Retained earnings	18	5,670,236,252	5,328,568,962
Non - controlling interest	19	1,225,990,411	1,154,626,813
<b>Total equity</b>		<b>19,189,711,809</b>	<b>18,748,978,811</b>
<b>Non-current liabilities</b>		<b>13,255,941,300</b>	<b>8,150,475,040</b>
Redeemable preference shares	Annexure-F	-	500,000,000
Provision for decommissioning of assets	Annexure-G	143,405,563	143,405,563
Long term loan	20	12,871,151,380	7,356,383,000
Lease obligation	21	46,909,046	26,573,217
Employee benefits payable	22	51,864,239	25,886,783
Deferred tax liability	23	142,611,072	98,226,477
<b>Current liabilities</b>		<b>4,395,453,657</b>	<b>4,090,964,256</b>
Current portion of long term loan	20.3	201,882,832	256,375,584
Current portion of lease obligation	21.1	38,345,934	15,417,560
Short term loans	24	565,995,722	565,283,464
Trade and other payables	25	3,185,123,864	2,590,499,077
Accrued expenses	26	404,105,305	663,388,571
<b>Total equity and liabilities</b>		<b>36,841,106,765</b>	<b>30,990,418,107</b>
<b>Number of shares used to compute NAV</b>		<b>234,000,000</b>	<b>234,000,000</b>
<b>Net asset value (NAV) including revaluation surplus</b>		<b>76.77</b>	<b>75.19</b>
<b>Net asset value (NAV) excluding revaluation surplus</b>		<b>68.69</b>	<b>66.98</b>

*The annexed notes form an integral part of these financial statements.*

**Managing Director**

**Director**

**Chief Financial Officer**

**Company Secretary**

*Signed in terms of our separate report of even date annexed.*

Dated, Dhaka;  
08 November 2020

**S F Ahmed & Co.**  
*Chartered Accountants*

**ORION PHARMA LIMITED**  
**Statement of Financial Position**  
**As at 30 June 2020**

	Notes	Amount in Taka	
		30 June 2020	30 June 2019
<b>Assets</b>			
<b>Non-current assets</b>		<b>13,041,155,930</b>	<b>12,040,783,721</b>
Property, plant and equipment	5a	7,860,572,660	5,246,736,287
Right of use Assets	6	50,347,853	-
Construction work-in-progress	7	1,651,460,156	3,369,075,037
Investment in subsidiaries	8	1,017,000,000	1,017,000,000
Investment in associate	9	319,403,000	254,282,000
Other investments	10	2,142,372,262	2,153,690,397
<b>Current assets</b>		<b>8,207,699,634</b>	<b>7,242,106,413</b>
Inventories	11a	345,170,358	270,587,251
Trade and other receivables	12a	5,920,737,952	6,020,796,815
Advances, deposits and prepayments	13a	1,291,850,015	907,965,205
Fixed deposit with banks	14	19,583,098	12,028,336
Cash and cash equivalents	15a	630,358,211	30,728,806
<b>Total assets</b>		<b>21,248,855,564</b>	<b>19,282,890,134</b>
<b>Shareholder's equity and liabilities</b>			
<b>Shareholder's equity</b>		<b>12,367,122,098</b>	<b>12,469,096,711</b>
Share capital	16	2,340,000,000	2,340,000,000
Share premium		8,016,892,026	8,016,892,026
Reserves	17a	1,552,679,134	1,509,109,947
Retained earnings	18a	457,550,939	603,094,738
<b>Non-current liabilities</b>		<b>7,201,719,921</b>	<b>5,091,407,432</b>
Long term loan	20a	6,987,470,945	4,940,720,955
Lease obligation	21	46,909,046	26,573,217
Employee benefits payable	22.a	24,728,858	25,886,783
Deferred tax liability	23	142,611,072	98,226,477
<b>Current liabilities</b>		<b>1,680,013,544</b>	<b>1,722,385,991</b>
Current portion long term loan	20.a.1	201,882,832	256,375,584
Current portion of lease obligation	21.1	38,345,934	15,417,560
Short term loans	24	565,995,722	565,283,464
Trade and other payables	25.a	603,503,932	623,062,003
Accrued expenses	26.a	270,285,125	262,247,380
<b>Total shareholder's equity and liabilities</b>		<b>21,248,855,564</b>	<b>19,282,890,134</b>
<b>Number of shares used to compute NAV</b>		<b>234,000,000</b>	<b>234,000,000</b>
<b>Net asset value (NAV) including revaluation surplus</b>		<b>52.85</b>	<b>53.29</b>
<b>Net asset value (NAV) excluding revaluation surplus</b>		<b>46.92</b>	<b>47.31</b>

*The annexed notes form an integral part of these financial statements.*

**Managing Director**

**Director**

**Chief Financial Officer**

**Company Secretary**

*Signed in terms of our separate report of even date annexed.*

Dated, Dhaka;  
08 November 2020

**S F Ahmed & Co.**  
Chartered Accountants

**ORION PHARMA LIMITED AND ITS SUBSIDIARIES**  
**Consolidated Statement of Profit or Loss and Other Comprehensive Income**  
**For the year ended 30 June 2020**

	Notes	Amount in Taka	
		01 July 2019 to 30 June 2020	01 July 2018 to 30 June 2019
Revenue from net sales	27	7,647,703,031	8,705,172,867
Cost of goods sold	28	(1,016,645,021)	(986,119,636)
Cost of power generation	29	(4,053,220,067)	(5,173,369,794)
<b>Gross profit</b>		<b>2,577,837,943</b>	<b>2,545,683,437</b>
<b>Operating expenses</b>		<b>(991,394,391)</b>	<b>(948,530,229)</b>
General and administrative expenses	30	(390,695,212)	(362,879,890)
Selling and distribution expenses	31	(600,699,179)	(585,650,340)
<b>Profit from operation</b>		<b>1,586,443,551</b>	<b>1,597,153,207</b>
Financial expenses	32	(792,229,161)	(577,625,205)
Interest and other income	33	41,092,252	22,249,730
<b>Net profit from operation</b>		<b>835,306,643</b>	<b>1,041,777,733</b>
Workers profit participation fund		(39,776,507)	(13,466,976)
<b>Net profit before tax</b>		<b>795,530,136</b>	<b>1,028,310,756</b>
<b>Income tax</b>		<b>(64,948,176)</b>	<b>(65,450,396)</b>
Current tax expenses	34	(17,777,911)	(44,244,820)
Deferred tax income/(expense)	23.1	(47,170,266)	(21,205,576)
<b>Net profit after tax</b>		<b>730,581,960</b>	<b>962,860,360</b>
Share of profit from associate	9	6,467,800	8,722,411
<b>Net profit for the year</b>		<b>737,049,760</b>	<b>971,582,771</b>
Less: Non controlling interest	19	(71,363,599)	(89,227,797)
<b>Net profit attributable to ordinary shareholders</b>		<b>665,686,161</b>	<b>882,354,974</b>
<b>Other comprehensive income</b>		<b>54,635,251</b>	<b>(14,264,018)</b>
Fair value gain/(loss) on marketable securities		(11,233,620)	(7,958,757)
Fair value gain/(loss) on investment in associates		63,331,730	(8,301,920)
Share of other comprehensive income of associate		(248,530)	22,510
Deferred tax income/(expenses) on revaluation surplus of PPE & fair value changes in marketable securities		2,785,671	1,974,149
<b>Total comprehensive income attributable to ordinary shareholders</b>		<b>720,321,411</b>	<b>868,090,956</b>
<b>Earning per share (EPS)</b>	35	<b>2.84</b>	<b>3.77</b>

*The annexed notes form an integral part of these financial statements.*

**Managing Director**

**Director**

**Chief Financial Officer**

**Company Secretary**

*Signed in terms of our separate report of even date annexed.*

Dated, Dhaka;  
08 November 2020

**S F Ahmed & Co.**  
Chartered Accountants

**ORION PHARMA LIMITED**  
**Statement of Profit or Loss and Other Comprehensive Income**  
**For the year ended 30 June 2020**

	Notes	Amount in Taka	
		01 July 2019 to 30 June 2020	01 July 2018 to 30 June 2019
Revenue from net sales	27a	2,297,740,301	2,222,541,814
Cost of goods sold	28	(1,016,645,021)	(986,119,636)
<b>Gross profit</b>		<b>1,281,095,280</b>	<b>1,236,422,177</b>
<b>Operating expenses</b>		<b>(902,584,790)</b>	<b>(858,597,090)</b>
General and administrative expenses	30a	(301,885,611)	(272,946,751)
Selling and distribution expenses	31	(600,699,179)	(585,650,340)
<b>Profit from operation</b>		<b>378,510,491</b>	<b>377,825,087</b>
Financial expenses	32a	(154,139,090)	(117,268,314)
Interest and other income	33	41,092,252	22,249,730
<b>Net profit from operation</b>		<b>265,463,653</b>	<b>282,806,504</b>
Workers profit participation fund		(12,641,126)	(13,466,976)
<b>Net profit before tax</b>		<b>252,822,527</b>	<b>269,339,528</b>
<b>Income tax</b>		<b>(64,948,176)</b>	<b>(65,450,396)</b>
Current tax expenses	34	(17,777,911)	(44,244,820)
Deferred tax income/(expense)	23.1	(47,170,266)	(21,205,576)
<b>Net profit after tax</b>		<b>187,874,350</b>	<b>203,889,131</b>
Share of profit from associate	9	6,467,800	8,722,411
<b>Net profit for the year</b>		<b>194,342,150</b>	<b>212,611,542</b>
<b>Other comprehensive income</b>		<b>54,635,251</b>	<b>(14,264,019)</b>
Fair value gain/(loss) of marketable securities		(11,233,620)	(7,958,757)
Fair value gain/(loss) on investment in associates		63,331,730	(8,301,921)
Share of other comprehensive income of associate		(248,530)	22,510
Deferred tax income/(expenses) on revaluation surplus of PPE & fair value changes of marketable securities		2,785,671	1,974,149
<b>Total comprehensive income attributable to ordinary shareholders</b>		<b>248,977,400</b>	<b>198,347,523</b>
<b>Earning per share (EPS)</b>	35a	<b>0.83</b>	<b>0.91</b>

*The annexed notes form an integral part of these financial statements.*

**Managing Director**

**Director**

**Chief Financial Officer**

**Company Secretary**

*Signed in terms of our separate report of even date annexed.*

Dated, Dhaka;  
08 November 2020

**S F Ahmed & Co.**  
*Chartered Accountants*

**ORION PHARMA LIMITED AND ITS SUBSIDIARIES**  
**Consolidated Statement of Changes in Equity**  
**For the year ended 30 June 2020**

*Amount in Taka*

Particulars	Ordinary Share Capital	Share Premium	Reserves	Retained Earnings	Sub Total	Non-Controlling Interest	Total
<b>Balance as at 01 July 2019</b>	<b>2,340,000,000</b>	<b>8,016,892,026</b>	<b>1,908,891,010</b>	<b>5,328,568,962</b>	<b>17,594,351,999</b>	<b>1,154,626,813</b>	<b>18,748,978,811</b>
Net profit after Tax	-	-	-	665,686,161	<b>665,686,161</b>	71,363,599	<b>737,049,760</b>
Fair value gain/(loss) on investment in associates	-	-	63,331,730	-	<b>63,331,730</b>	-	<b>63,331,730</b>
Dividend for the year 2018-2019	-	-	-	(351,000,000)	<b>(351,000,000)</b>	-	<b>(351,000,000)</b>
Adjustment for sale of marketable securities	-	-	47,987	-	<b>47,987</b>	-	<b>47,987</b>
Fair value gain/(loss) on marketable securities	-	-	(11,233,620)	-	<b>(11,233,620)</b>	-	<b>(11,233,620)</b>
Share of other comprehensive income of associate	-	-	(248,530)	-	<b>(248,530)</b>	-	<b>(248,530)</b>
Adjustment for deferred tax on revaluation surplus	-	-	2,785,671	-	<b>2,785,671</b>	-	<b>2,785,671</b>
Depreciation on revaluation surplus	-	-	(26,981,129)	26,981,129	-	-	-
<b>Balance as at 30 June 2020</b>	<b>2,340,000,000</b>	<b>8,016,892,026</b>	<b>1,936,593,119</b>	<b>5,670,236,252</b>	<b>17,963,721,397</b>	<b>1,225,990,411</b>	<b>19,189,711,809</b>

**ORION PHARMA LIMITED AND ITS SUBSIDIARIES**  
**Consolidated Statement of Changes in Equity**  
**For the year ended 30 June 2019**

Particulars	Ordinary Share Capital	Share Premium	Reserves	Retained Earnings	Sub Total	Non-Controlling Interest	Total
<b>Balance as at 01 July 2018</b>	<b>2,340,000,000</b>	<b>8,016,892,026</b>	<b>1,944,512,924</b>	<b>4,752,806,311</b>	<b>17,054,211,261</b>	<b>1,065,399,016</b>	<b>18,119,610,277</b>
Prior year adjustment	-	-	-	15,956,766	<b>15,956,766</b>	-	<b>15,956,766</b>
Net profit after tax	-	-	-	882,354,974	<b>882,354,974</b>	89,227,797	<b>971,582,771</b>
Fair value gain/(loss) on investment in associates	-	-	(8,301,921)	-	<b>(8,301,921)</b>	-	<b>(8,301,921)</b>
Dividend for the year 2017-2018	-	-	-	(351,000,000)	<b>(351,000,000)</b>	-	<b>(351,000,000)</b>
Adjustment for sale of marketable securities	-	-	7,093,015	-	<b>7,093,015</b>	-	<b>7,093,015</b>
Fair value gain/(loss) on marketable securities	-	-	(7,958,757)	-	<b>(7,958,757)</b>	-	<b>(7,958,757)</b>
Share of other comprehensive income	-	-	22,510	-	<b>22,510</b>	-	<b>22,510</b>
Adjustment for deferred tax on revaluation surplus	-	-	1,974,149	-	<b>1,974,149</b>	-	<b>1,974,149</b>
Adjustment for depreciation on revaluation surplus	-	-	(28,450,911)	28,450,911	-	-	-
<b>Balance as at 30 June 2019</b>	<b>2,340,000,000</b>	<b>8,016,892,026</b>	<b>1,908,891,010</b>	<b>5,328,568,962</b>	<b>17,594,351,998</b>	<b>1,154,626,813</b>	<b>18,748,978,811</b>

Managing Director

Director

Chief Financial Officer

Company Secretary

Dated, Dhaka;  
08 November 2020

**S F Ahmed & Co.**  
Chartered Accountants

**ORION PHARMA LIMITED**  
**Statement of Changes in Equity**  
**For the year ended 30 June 2020**

Particulars	Amount in Taka				
	Ordinary Share Capital	Share Premium	Reserves	Retained Earnings	Total
<b>Balance as at 01 July 2019</b>	<b>2,340,000,000</b>	<b>8,016,892,026</b>	<b>1,509,109,947</b>	<b>603,094,738</b>	<b>12,469,096,711</b>
Net profit after tax	-	-	-	194,342,150	<b>194,342,150</b>
Dividend for the period 2018- 2019	-	-	-	(351,000,000)	<b>(351,000,000)</b>
Fair value gain/(loss) on investment in associates	-	-	63,331,730	-	<b>63,331,730</b>
Share of other comprehensive income of associate	-	-	(248,530)	-	<b>(248,530)</b>
Adjustment for sale of marketable securities	-	-	47,987	-	<b>47,987</b>
Fair value gain/(loss) on marketable securities	-	-	(11,233,620)	-	<b>(11,233,620)</b>
Adjustment for deferred tax on revaluation surplus	-	-	2,785,671	-	<b>2,785,671</b>
Adjustment for depreciation on revaluation surplus	-	-	(11,114,051)	11,114,051	-
<b>Balance as at 30 June 2020</b>	<b>2,340,000,000</b>	<b>8,016,892,026</b>	<b>1,552,679,134</b>	<b>457,550,939</b>	<b>12,367,122,098</b>

**ORION PHARMA LIMITED**  
**Statement of Changes in Equity**  
**For the year ended 30 June 2019**

Particulars	Amount in Taka				
	Ordinary Share Capital	Share Premium	Reserves	Retained Earnings	Total
<b>Balance at 01 July 2018</b>	<b>2,340,000,000</b>	<b>8,016,892,026</b>	<b>1,528,864,782</b>	<b>712,942,598</b>	<b>12,598,699,407</b>
Prior year adjustment	-	-	-	15,956,766	<b>15,956,766</b>
Net profit after tax	-	-	-	212,611,542	<b>212,611,542</b>
Dividend for the period 2017- 2018	-	-	-	(351,000,000)	<b>(351,000,000)</b>
Fair value gain/(loss) on investment in associates	-	-	(8,301,921)	-	<b>(8,301,921)</b>
Share of other comprehensive income of associates	-	-	22,510	-	<b>22,510</b>
Adjustment for sale of marketable securities	-	-	7,093,015	-	<b>7,093,015</b>
Fair value gain/(loss) on marketable securities	-	-	(7,958,757)	-	<b>(7,958,757)</b>
Adjustment for deferred tax on revaluation surplus	-	-	1,974,149	-	<b>1,974,149</b>
Adjustment for depreciation on revaluation surplus	-	-	(12,583,832)	12,583,832	-
<b>Balance as at 30 June 2019</b>	<b>2,340,000,000</b>	<b>8,016,892,026</b>	<b>1,509,109,947</b>	<b>603,094,738</b>	<b>12,469,096,711</b>

Managing Director

Director

Chief Financial Officer

Company Secretary

Dated, Dhaka;  
08 November 2020

S F Ahmed & Co.  
Chartered Accountants

**ORION PHARMA LIMITED AND ITS SUBSIDIARIES**  
**Consolidated Statement of Cash Flows**  
**For the year ended 30 June 2020**

Notes	Amount in Taka	
	01 July 2019 to 30 June 2020	01 July 2018 to 30 June 2019

**A. Cash flows from operating activities**

Cash received from customers and others	6,686,325,836	9,692,190,702
Cash paid to suppliers and others	(3,951,502,857)	(7,394,162,508)
Cash payment for operating expenses	(816,026,026)	(801,728,472)
<b>Cash generated from operations</b>	<b>1,918,796,953</b>	<b>1,496,299,722</b>
Income taxes paid	(36,465,342)	(47,752,252)
<b>Net cash (used in)/ provided by operating activities</b>	<b>1,882,331,611</b>	<b>1,448,547,470</b>

36

**B. Cash flows from investing activities**

Acquisition of property, plant & equipment	(646,393,821)	(815,813,155)
Proceeds from sale of PPE	5,795,000	1,350,000
Capital work-in-progress	(897,060,499)	(532,643,067)
Investment in securities and others	132,503	18,677,590
Investment in subsidiaries, associate and others	89,970,348	(461,351,605)
Investment in FDR	(7,554,761)	(4,463,074)
Interest, dividend & other income	36,396,540	21,999,242
<b>Net cash (used in)/ provided by investing activities</b>	<b>(1,418,714,691)</b>	<b>(1,772,244,069)</b>

**C. Cash flows from financing activities**

Proceed from/(repayment of) long term loan	4,960,275,628	926,249,112
Proceed from/(repayment of) short term loan	(3,008,814,249)	(78,693,428)
Payment of lease obligation	(34,542,816)	(7,582,425)
Interest paid	(1,065,485,018)	(594,953,758)
Dividend paid	(373,059,566)	(336,185,883)
<b>Net cash (used in)/ provided by financing activities</b>	<b>478,373,979</b>	<b>(91,166,381)</b>

<b>Net cash increase/(decrease) during the year (A+B+C)</b>	<b>941,990,899</b>	<b>(414,862,980)</b>
Cash & cash equivalents at the beginning of the year	92,187,429	507,050,409
<b>Cash &amp; cash equivalents at the end of the year</b>	<b>1,034,178,328</b>	<b>92,187,429</b>
<b>Net operating cash flows per share (NOCFPS)</b>	<b>8.04</b>	<b>6.19</b>

36.1

Managing Director

Director

Chief Financial Officer

Company Secretary

Dated, Dhaka;

08 November 2020

**ORION PHARMA LIMITED**  
**Statement of Cash Flows**  
**For the year ended 30 June 2020**

Notes	Amount in Taka	
	01 July 2019 to 30 June 2020	01 July 2018 to 30 June 2019

**A. Cash flows from operating activities**

Cash received from customers and others	2,312,676,543	2,194,277,763
Cash paid to suppliers and others	(874,143,337)	(761,305,773)
Cash payment for operating expenses	(816,026,026)	(801,728,472)
<b>Cash generated from operations</b>	<b>622,507,180</b>	<b>631,243,518</b>
Income taxes paid	(36,465,342)	(47,752,252)
<b>Net cash (used in)/provided by operating activities</b>	<b>586,041,838</b>	<b>583,491,267</b>

36a

**B. Cash flows from investing activities**

Acquisition of property, plant & equipment	(645,319,587)	(809,807,368)
Proceeds from sale of PPE	5,795,000	1,350,000
Capital work-in-progress	(897,060,499)	(532,643,067)
Investment in securities and others	132,503	18,677,590
Investment in subsidiaries, associate and others	89,970,348	(461,351,605)
Investment in FDR	(7,554,761)	(4,463,074)
Interest, dividend & other income	36,396,540	21,999,242
<b>Net cash (used in)/provided by investing activities</b>	<b>(1,417,640,457)</b>	<b>(1,766,238,282)</b>

**C. Cash flows from financing activities**

Proceed from/(repayment of) long term loan	1,992,257,238	1,358,925,234
Proceed from/(repayment of) short term loan	712,258	(17,067,801)
Payment of lease obligation	(34,542,816)	(7,582,425)
Interest paid	(154,139,091)	(117,268,315)
Dividend paid	(373,059,566)	(336,185,883)
<b>Net cash (used in)/provided by financing activities</b>	<b>1,431,228,024</b>	<b>880,820,810</b>

<b>Net cash increase/(decrease) during the year (A+B+C)</b>	<b>599,629,405</b>	<b>(301,926,204)</b>
Cash & cash equivalents at the beginning of the year	30,728,806	332,655,011
<b>Cash &amp; cash equivalents at the end of the year</b>	<b>630,358,211</b>	<b>30,728,806</b>
<b>Net operating cash flows per share ( NOCFPS)</b>	<b>2.50</b>	<b>2.49</b>

36a.1

**Managing Director**

**Director**

**Chief Financial Officer**

**Company Secretary**

Dated, Dhaka;  
08 November 2020

		Amount in Taka			
		30 June 2020	30 June 2019		
<b>5. Property, plant and equipment</b>					
Opening balance		12,937,529,084	13,144,226,580		
Add: Addition during the year		2,904,286,804	616,465,384		
Less: Sale /disposal during the year		(1,517,015)	(1,099,512)		
		<b>15,840,298,873</b>	<b>13,759,592,453</b>		
Less: Depreciation charged during the year		(909,356,636)	(822,063,368)		
<b>Written down value</b>		<b>14,930,942,237</b>	<b>12,937,529,084</b>		
<b>Details have been presented in Annexure - A.1</b>					
<b>5a. Property, plant and equipment</b>					
Opening balance		5,246,736,287	4,809,521,233		
Add: Addition during the year		2,903,212,570	610,459,597		
Less: Sale /disposal during the year		(1,517,015)	(1,099,512)		
		<b>8,148,431,842</b>	<b>5,418,881,318</b>		
Less: Depreciation charged during the year		(287,859,182)	(172,145,031)		
<b>Written down value</b>		<b>7,860,572,660</b>	<b>5,246,736,287</b>		
<b>Details have been presented in Annexure - A.2</b>					
<b>6. Right of use Assets</b>					
Opening Balance		-	-		
Add: Addition During the Year		77,807,019	-		
		<b>77,807,019</b>	-		
Less: Depreciation charged during the year		(27,459,166)	-		
		<b>50,347,853</b>	-		
<b>Details have been shown in Annexure - B</b>					
<b>7. Construction work in progress</b>					
Opening balance		3,369,075,037	2,836,431,969		
Add: Addition during the year		897,060,499	532,643,067		
Less: Transferred to PPE		(2,614,675,380)	-		
Closing balance		<b>1,651,460,156</b>	<b>3,369,075,037</b>		
A state of the art factory is being constructed at Siddirgonj, Narayangonj to increase the overall production capacity of the company. In relation to that purpose substantial amount has been transferred to PPE from CWIP					
<b>8. Investment in subsidiaries</b>					
Name of the subsidiary company	Number of shares	Share holding (%)		Amount in Taka	
		30 June 2020	30 June 2019	30 June 2020	30 June 2019
Orion Power Meghnaghat Ltd.	95,000,000	95.00	95.00	950,000,000	950,000,000
Dutch Bangla Power & Associates Ltd.	6,700,000	67.00	67.00	67,000,000	67,000,000
<b>Total</b>				<b>1,017,000,000</b>	<b>1,017,000,000</b>
Investment in subsidiaries are stated at cost.					
<b>9. Investment in associate</b>					
<b>Orion Infusion Limited</b>					
Opening balance		254,282,000	260,041,000		
Add: Share of profit during the year		6,467,800	8,722,411		
Less: Dividend during the year		(4,430,000)	(6,202,000)		
Add: Share of other comprehensive income		(248,530)	22,510		
Add: Fair value adjustment		63,331,730	(8,301,921)		
		<b>319,403,000</b>	<b>254,282,000</b>		
<b>10. Other investment</b>					
Investment in marketable securities (Note 10.1)		23,916,586	35,234,721		
Investment in non-Quoted Shares (Note 10.2)		2,118,455,676	2,118,455,676		
		<b>2,142,372,262</b>	<b>2,153,690,397</b>		
<b>10.1 Investment in marketable securities</b>					
AB Investment Limited.		13,946,191	19,849,892		
Bank Asia Securities Limited.		3,772,363	6,018,329		
LankaBangla Securities Ltd		6,198,032	9,366,500		
		<b>23,916,586</b>	<b>35,234,721</b>		

Details have been presented in Annexure - C

**10.2 Investment in non-quoted shares**

	Amount in Taka	
	30 June 2020	30 June 2019
Orion Power Khulna Limited.	500,000	500,000
Orion Power Dhaka Limited.	500,000	500,000
ICB Islami Bank Limited	246,000	246,000
Orion Infrastructure Limited.	2,117,209,676	2,117,209,676
	<b>2,118,455,676</b>	<b>2,118,455,676</b>

**11. Inventories**

Raw materials	145,426,337	126,896,948
Packing materials	68,227,685	42,072,240
Work-in-process	17,129,910	13,817,389
Finished goods	75,769,179	44,674,750
Printing Stationeries	2,826,678	2,700,130
Promotional materials	6,114,954	4,775,586
Goods in transit	434,800,503	136,980,104
Mobil & Chemical	-	66,152,627
Spare parts	340,123,417	399,272,958
Inventory HFO & LFO	187,202,025	80,708,877
	<b>1,277,620,688</b>	<b>918,051,609</b>

**11.a Inventories**

Raw materials	145,426,337	126,896,948
Packing materials	68,227,685	42,072,240
Work-in-process	17,129,910	13,817,389
Finished goods	75,769,179	44,674,750
Printing Stationeries	2,826,678	2,700,130
Promotional materials	6,114,954	4,775,586
Goods in transit	29,675,615	35,650,208
	<b>345,170,358</b>	<b>270,587,251</b>

**12. Trade & other receivables**

Trade receivables	2,661,828,822	1,700,033,898
Other receivables (Note-12.1)	8,986,830,305	8,407,977,688
	<b>11,648,659,127</b>	<b>10,108,011,586</b>

Trade receivables are unsecured, considered good and recoverable within one year. Classification schedules as required by schedule XI of Companies Act 1994 are as follows:

**Ageing of the above balance is as follows:**

Below 180 days	2,661,828,822	1,700,033,898
Above 180 days	-	-
	<b>2,661,828,822</b>	<b>1,700,033,898</b>

SL. No.	Particulars	Amount in Taka	
		30 June 2020	30 June 2019
I	Trade receivables considered good in respect of which the company is fully secured	2,661,828,822	1,700,033,898
II	Trade receivables considered good in respect of which the company holds no security other than the debtor personal security	-	-
III	Trade receivables considered doubtful or bad	-	-
IV	Trade receivables due by any director or other officer of the company	-	-
V	Trade receivables due by common management	-	-
VI	The maximum amount of receivable due by any director or other officer of the company	-	-
	<b>Total</b>	<b>2,661,828,822</b>	<b>1,700,033,898</b>

As on 30 June 2020 the company did not make any provision on the trade receivable as was no indication of impairment.

**12.1 Other receivables**

Claim receivables, insurance & others	3,064,643	2,158,262
Divided receivable	4,430,000	6,202,000
Interest on FDR	165,532	260,876
Other receivables	209,566,675	179,159,898
Current account with other related companies (Note. 12.1.1)	8,769,603,456	8,220,196,653
	<b>8,986,830,305</b>	<b>8,407,977,688</b>

Amount in Taka	
30 June 2020	30 June 2019

#### 12.1.1 Current account with other related companies

Noakhali Gold Food Ltd.	33,129,928	24,974,785
Orion Properties Ltd.	33,871,089	33,871,089
Orion Gas Limited	49,200,000	49,200,000
Orion Power Khulna Ltd.	1,029,967,694	1,029,967,694
Orion Power Dhaka Ltd.	2,431,298,916	2,412,647,852
Jafflong Tea Company	2,408,371	2,408,371
Orion Agro Product	240,118,758	235,180,820
Interior Accom Consortium Limited	155,495,459	155,495,459
Digital Power & Associate Ltd.	444,684,971	327,635,887
Orion Footwear Ltd.	107,775,395	91,600,000
Orion Oil & Shipping Ltd.	215,230,919	151,412,851
Panbo Bangla Mashroom Ltd.	115,006,570	108,235,190
Orion Power Unit 2 Dhaka Ltd.	2,178,093,169	2,590,024,972
Orion Home Appliance Ltd.	47,848,000	7,848,000
Orion Knit Textiles Ltd.	220,544,115	219,000,000
Orion Hospitals Ltd.	16,500,000	4,400,000
Orion Power Rupsha Ltd.	305,033,401	245,563,731
Orion Power Sonargaon Ltd.	1,001,896,701	529,229,951
Energon Renewable (BD) Ltd.	1,500,000	1,500,000
Orion Quaderia Textiles Limited	130,000,000	-
Horizon Media & Publications Limited	10,000,000	-
	<b>8,769,603,456</b>	<b>8,220,196,653</b>

#### 12.a Trade & other receivables

Trade receivables	155,652,117	170,170,631
Other receivables (Note - 12a.1)	5,765,085,835	5,850,626,184
	<b>5,920,737,952</b>	<b>6,020,796,815</b>

Trade receivables are unsecured, considered good and recoverable within one year. Classification schedules as required by schedule XI of Companies Act 1994 are as follows:

##### Ageing of the above balance is as follows:

Below 180 days	155,652,117	170,170,631
Above 180 days	-	-
	<b>155,652,117</b>	<b>170,170,631</b>

SL No	Particulars	Amount in Tk	
		30 June 2020	30 June 2019
I	Trade receivables considered good in respect of which the company is fully secured	155,652,117	170,170,631
II	Trade receivables considered good in respect of which the company holds no security other than the debtor personal security	-	-
III	Trade receivables considered doubtful or bad	-	-
IV	Trade receivables due by any director or other officer of the company	-	-
V	Trade receivables due by common management	-	-
VI	The maximum amount of receivable due by any director or other officer of the company	-	-
	<b>Total</b>	<b>155,652,117</b>	<b>170,170,631</b>

As on 30 June 2020 the company did not make any provision on the trade receivable as was no indication of impairment.

#### 12a.1 Other receivables

Claim receivables, insurance & others	3,064,643	2,158,262
Divided receivable	4,430,000	6,202,000
Interest on FDR	165,532	260,876
Other receivables	209,566,675	179,159,898
Current account with subsidiaries (12a.1.1)	369,399,764	370,748,526
Current account with other related companies (12a.1.2)	5,178,459,222	5,292,096,622
	<b>5,765,085,835</b>	<b>5,850,626,184</b>

#### 12a.1.1 Current account with subsidiaries

Dutch Bangla Power & Associates Limited.	369,399,764	370,748,526
	<b>369,399,764</b>	<b>370,748,526</b>

		Amount in Taka	
		30 June 2020	30 June 2019
<b>12a.1.2 Current account with other related companies</b>			
Orion Properties Ltd.	20,331,532	20,331,532	
Orion Power Khulna Ltd.	986,021,913	986,021,913	
Orion Power Dhaka Ltd.	2,176,293,707	2,176,293,707	
Interior Accom Consortium Ltd.	107,995,459	107,995,459	
Orion Agro Product Ltd.	232,265,920	232,265,920	
Orion Power Unit -2 Dhaka Ltd.	1,358,708,776	1,483,046,176	
Orion Power Rupsha Ltd.	186,800,000	186,800,000	
Digital Power & Associates Ltd.	97,341,915	97,341,915	
Orion Hospitals Ltd.	12,700,000	2,000,000	
	<b>5,178,459,222</b>	<b>5,292,096,622</b>	
<b>13. Advances, deposits and prepayments</b>			
<b>Advances:</b>			
Advance income tax (Note-13.1)	133,033,784	104,849,701	
Advance imprest money	43,000	114,000	
Advance motor cycle	14,630,196	17,589,968	
Advance - car loan	2,976,934	2,216,569	
Collection advance	5,455,130	6,237,861	
Advance to C&F agents	1,382,576	2,271,727	
Advance to Supplier	225,604,358	203,211,611	
Advance against land purchase	325,000,000	325,000,000	
Advance against material loan	2,381,414	1,084,773	
Advance office rent	6,898,673	5,277,769	
Advance to employee	3,867,815	8,481,024	
Other advance	2,037,716,920	125,132,500	
Advance to depot	-	2,862,079	
Advance for Impoted machinery	640,756,566	198,365,774	
	<b>3,399,747,367</b>	<b>1,002,695,356</b>	
<b>Deposits:</b>			
Earnest money	455,000	1,311,770	
Security deposit	45,422,826	44,953,056	
Bank guarantee	69,712,449	68,853,576	
L/C margin	191,656,453	11,661,282	
VAT current account	-	2,087	
Lease deposit	15,021,334	11,917,725	
	<b>322,268,062</b>	<b>138,699,495</b>	
<b>Prepayments:</b>			
Insurance premium	953,003	321,119	
Bank gurantee,commission & charge	43,571,585	2,829,138	
Deferred expenses	-	1,017,520	
	<b>44,524,588</b>	<b>4,167,777</b>	
	<b>3,766,540,017</b>	<b>1,145,562,629</b>	
<b>13.1 Advance income tax</b>			
Opening balance	104,849,700	63,999,535	
Add: Addition during the year	28,184,084	24,893,400	
	<b>133,033,784</b>	<b>88,892,935</b>	
Less: Adjustment of assessment for previous	-	15,956,766	
Closing balance	<b>133,033,784</b>	<b>104,849,701</b>	
<b>13.a Advances, deposits &amp; prepayments</b>			
<b>Advances:</b>			
Advance income tax (Note -13a.1)	131,716,484	103,789,126	
Advance imprest money	43,000	114,000	
Motor cycle advance	14,630,196	17,589,968	
Advance - car loan	2,976,934	2,216,569	
Collection advance	5,455,130	6,237,861	
Advance to C&F agents	1,382,576	2,271,727	
Advance against material loan	2,381,414	1,084,773	
Advance office rent	6,898,673	5,277,769	
Advance against land purchase	325,000,000	325,000,000	
Machinery & equipment	75,093,648	177,470,072	
Electrical equipment	359,486	656,915	
Construction	31,008,033	13,942,575	
Advance for Impoted machinery	640,756,566	198,365,774	
Advance to depot	-	2,862,079	
	<b>1,237,702,141</b>	<b>856,879,207</b>	

		Amount in Taka	
		30 June 2020	30 June 2019
<b>Deposits</b>			
Earnest money		455,000	1,311,770
Security deposit		34,911,306	34,953,056
Bank guarantee		4,217,634	3,358,761
VAT current account		-	2,087
Lease deposit		14,563,934	11,460,324
		<b>54,147,874</b>	<b>51,085,998</b>
		<b>1,291,850,015</b>	<b>907,965,205</b>
All advances, deposits and prepayments are considered regular and recoverable in the normal course of business.			
<b>13a.1 Advance income tax</b>			
Opening balance		103,789,126	63,118,101
Addition during the year		27,927,358	24,714,260
Less: Adjustment of assessment for previous		-	15,956,766
<b>Closing balance</b>		<b>131,716,484</b>	<b>103,789,126</b>
<b>14. Fixed deposit with banks</b>			
Social Islami Bank Limited., Principal Branch, Dhaka.		8,512,435	8,028,336
Agrani Bank Ltd.		11,070,663	4,000,000
		<b>19,583,098</b>	<b>12,028,336</b>
Details have been presented in Annexure -D			
<b>15. Cash &amp; cash equivalents</b>			
Cash in hand (Note -15.1)		10,613,804	9,995,563
Cash at B/O account (Note -15.2)		93,022	7,830
		<b>10,706,826</b>	<b>10,003,393</b>
<b>Balance with banks on account</b>			
Current account		420,797,288	66,357,659
Short term deposit account		602,674,214	15,826,377
		<b>1,023,471,502</b>	<b>82,184,036</b>
		<b>1,034,178,328</b>	<b>92,187,429</b>
<b>15.1 Cash in hand</b>			
Head office		4,972,534	6,334,646
Depot office		5,641,270	3,660,917
		<b>10,613,804</b>	<b>9,995,563</b>
<b>15.2 Cash at B/O account</b>			
Bank Asia Securities Limited.		89,350	4,493
Jahan Securities Limited.		2,874	3,324
LankaBangla Securities Ltd		798	14
		<b>93,022</b>	<b>7,830</b>
<b>15.a Cash and cash equivalents</b>			
Cash in hand (Note -15a.1)		8,445,688	8,967,393
Cash at B/O account (Note -15a.2)		93,022	7,830
		<b>8,538,710</b>	<b>8,975,223</b>
<b>Cash at Bank:</b>			
Current account		19,145,287	15,826,377
Short term deposit account		602,674,214	5,927,206
<b>Details have been presented in Annexure-E</b>		<b>621,819,501</b>	<b>21,753,583</b>
		<b>630,358,211</b>	<b>30,728,806</b>
<b>15a.1 Cash in hand</b>			
Head office - central cash & main cash		2,804,418	5,306,476
Depot office - petty cash		5,641,270	3,660,917
		<b>8,445,688</b>	<b>8,967,393</b>
<b>15a.2 Cash at B/O account</b>			
Bank Asia Securities Limited.		89,350	4,493
Jahan Securities Limited.		2,874	3,324
LankaBangla Securities Ltd.		798	14
		<b>93,022</b>	<b>7,830</b>

Amount in Taka	
30 June 2020	30 June 2019

## 16. Share capital

### Authorized capital

500,000,000 ordinary shares of Tk. 10 each

5,000,000,000	5,000,000,000
---------------	---------------

### Issued, subscribed and paid-up capital

234,000,000 ordinary shares of Tk. 10 each

2,340,000,000	2,340,000,000
---------------	---------------

### Shareholding position of the company

Range of Shareholding	Number of Shareholders	Number of Shares	% of holding	
			30 June 2020	30 June 2019
Up to 500 Shares	28,404	3,207,721	1.37	0.76
501 to 5,000 Shares	5,219	10,358,814	4.43	3.08
5001 to 10,000 Shares	944	6,836,575	2.92	2.30
10,001 to 20,000 Shares	510	7,147,643	3.05	2.61
20,001 to above	404	206,449,247	88.23	91.24
<b>Total</b>	<b>35,481</b>	<b>234,000,000</b>	<b>100.00</b>	<b>100.00</b>

Categories of shareholders	Number of Shareholders	Number of Shares	% of holding	
			30 June 2020	30 June 2019
Sponsors	5	74,841,600	31.98	31.98
Foreign Investor	153	3,852,998	1.65	2.59
Financial institutions	189	109,366,464	46.74	48.12
General public	35,134	45,938,938	19.63	17.31
<b>Total</b>	<b>35,481</b>	<b>234,000,000</b>	<b>100.00</b>	<b>100.00</b>

Orion Power Meghnaghat Limited	Number of Shares	30 June 2020		30 June 2019	
		Face Value	% of holding	Face Value	Total
Orion Pharma Limited	95,000,000	950,000,000	95.00%	950,000,000	95.00%
Integral Energy Limited	3,000,000	30,000,000	3.00%	30,000,000	3.00%
Jafflong Tea Company Limited	500,000	5,000,000	0.50%	5,000,000	0.50%
Mr. Mohammad Obaidul Karim	500,000	5,000,000	0.50%	5,000,000	0.50%
Mr. Salman Obaidul Karim	600,000	6,000,000	0.60%	6,000,000	0.60%
Mrs. Arzuda Karim	350,000	3,500,000	0.35%	3,500,000	0.35%
Haarhuis Generation B.V.	50,000	500,000	0.05%	500,000	0.05%
<b>Total</b>	<b>100,000,000</b>	<b>1,000,000,000</b>	<b>100%</b>	<b>1,000,000,000</b>	<b>100%</b>

Dutch Bangla Power & Associates Limited	Number of Shares	30 June 2020		30 June 2019	
		Face Value	% of holding	Face Value	% of holding
Orion Pharma Limited	6,700,000	67,000,000	67.00%	67,000,000	67.00%
Shenzhen Nanshan Power Co. Ltd.	50,000	500,000	0.50%	500,000	0.50%
Mohammad Obaidul Karim	100,000	1,000,000	1.00%	1,000,000	1.00%
Salman Obaidul Karim	3,087,500	30,875,000	30.88%	30,875,000	30.88%
Orion Tea Company Ltd.	50,000	500,000	0.50%	500,000	0.50%
Jafflong Tea Co. Ltd.	2,500	25,000	0.03%	25,000	0.03%
Mrs. Arzuda Karim	10,000	100,000	0.10%	100,000	0.10%
<b>Total</b>	<b>10,000,000</b>	<b>100,000,000</b>	<b>100%</b>	<b>100,000,000</b>	<b>100%</b>

## 17. Reserves

Fair value gain/(loss) on investment in associate (Note -17.1)	237,175,941	173,844,211
Fair value gain /(loss) on marketable securities (Note -17.2)	(22,090,059)	(12,022,989)
Share of other comprehensive income of associate (Note - 17.3)	5,748,129	5,996,659
Revaluation surplus on property, plant and equipment (Note -17.4)	1,715,759,107	1,741,073,129
	<b>1,936,593,119</b>	<b>1,908,891,010</b>

### 17.1 Fair value gain on investment in associate

Opening balance	173,844,211	182,146,131
Fair value gain/ (loss) during the year	63,331,730	(8,301,920)
	<b>237,175,941</b>	<b>173,844,211</b>

		Amount in Taka	
		30 June 2020	30 June 2019
<b>17.2 Fair value gain/(loss) on marketable securities</b>			
Opening balance	(12,022,989)	(11,243,821)	
Adjustment of sale of marketable securities	47,987	7,093,015	
Fair value gain/(loss) on marketable securities (Note - 17.2.1)	(11,233,620)	(7,958,757)	
Transferred to deferred tax assets/(liabilities)	1,118,563	86,574	
	<b>(22,090,059)</b>	<b>(12,022,989)</b>	
<b>17.2.1 Fair value gain/(loss) on marketable securities during the year</b>			
Unrealized gain/(loss) position (closing)	(24,544,509)	(13,358,875)	
Unrealized gain/(loss) position (opening)	(13,358,875)	(12,493,134)	
<b>Total change during the year</b>	<b>(11,185,633)</b>	<b>(865,742)</b>	
Fair value adjustment for sale of securities (realized loss)	(47,987)	(7,093,015)	
<b>Unrealized gain/(loss) during the year</b>	<b>(11,233,620)</b>	<b>(7,958,757)</b>	
<b>17.3 Share of other comprehensive income</b>			
Opening balance	5,996,659	5,974,149	
Add: Addition during the year	(248,530)	22,510	
	<b>5,748,129</b>	<b>5,996,659</b>	
<b>17.4 Revaluation surplus on property, plant &amp; equipment</b>			
Opening balance	1,741,073,129	1,767,636,465	
Adjustment during the year to retained earnings for depreciation	(26,981,129)	(28,450,911)	
Adjustment of deferred tax on revaluation surplus	1,667,108	1,887,575	
	<b>1,715,759,107</b>	<b>1,741,073,129</b>	
<b>17.a Reserve</b>			
Fair value gain on investment in associates (Note - 17a.1)	237,175,941	173,844,211	
Fair value gain/(loss) on marketable securities (Note - 17a.2)	(22,090,058)	(12,022,988)	
Share of other comprehensive income (Note - 17a.3)	5,748,128	5,996,659	
Revaluation surplus on property, plant & equipment (Note - 17a.4)	1,331,845,122	1,341,292,066	
	<b>1,552,679,134</b>	<b>1,509,109,947</b>	
<b>17a.1 Fair value gain on investment in associates</b>			
Opening balance	173,844,211	182,146,132	
Fair value gain/(loss) during the year	63,331,730	(8,301,921)	
	<b>237,175,941</b>	<b>173,844,211</b>	
<b>17a.2 Fair value gain/(loss) on marketable securities</b>			
Opening balance	(12,022,988)	(11,243,821)	
Adjustment of sale of marketable securities	47,987	7,093,015	
Fair value gain/(loss) on marketable securities D/Y (Note - 17a.2.1)	(11,233,620)	(7,958,757)	
Transferred to deferred tax assets/(liabilities)	1,118,563	86,574	
	<b>(22,090,058)</b>	<b>(12,022,988)</b>	
<b>17a.2.1 Fair value gain/(loss) on marketable securities during the year</b>			
Unrealized gain/(loss) position (closing)	(24,544,509)	(13,358,875)	
Unrealized gain/(loss) position (opening)	(13,358,875)	(12,493,134)	
Fair value adjustment for sale of securities realized gain/(loss)	(47,987)	(7,093,015)	
<b>Unrealized gain/(loss) during the year</b>	<b>(11,233,620)</b>	<b>(7,958,757)</b>	
<b>17a.3 Share of other comprehensive income</b>			
Opening balance	5,996,659	5,974,148	
Add: Addition during the year	(248,530)	22,510	
	<b>5,748,128</b>	<b>5,996,659</b>	
<b>17a.4 Revaluation surplus on property, plant &amp; equipment</b>			
Opening balance	1,341,292,066	1,351,988,323	
Adjustment during the year to retained earnings for depreciation	(11,114,051)	(12,583,832)	
Adjustment of deferred tax on revaluation surplus	1,667,108	1,887,575	
	<b>1,331,845,122</b>	<b>1,341,292,066</b>	

		Amount in Taka	
		30 June 2020	30 June 2019
<b>18. Retained earnings</b>			
Opening balance	5,328,568,962	4,752,806,311	
Prior year adjustment	-	15,956,766	
	<b>5,328,568,962</b>	<b>4,768,763,077</b>	
Net profit after tax	665,686,161	882,354,974	
Dividend for the year	(351,000,000)	(351,000,000)	
Adjustment for depreciation on revaluation surplus	26,981,129	28,450,911	
	<b>5,670,236,252</b>	<b>5,328,568,962</b>	
<b>18.a Retained Earnings</b>			
Opening balance	603,094,738	712,942,599	
Adjustment for previous years tax assessment	-	15,956,766	
Net profit after tax	194,342,150	212,611,542	
Dividend for the year	(351,000,000)	(351,000,000)	
Adjustment for depreciation on revaluation surplus	11,114,051	12,583,832	
	<b>457,550,939</b>	<b>603,094,738</b>	
<b>19. Non-controlling interest</b>			
Opening balance	1,154,626,813	1,065,399,016	
Share of operating profit	71,363,599	89,227,797	
Closing balance	<b>1,225,990,411</b>	<b>1,154,626,813</b>	
<b>20. Long term loan</b>			
Syndicated loan and other long term loans (Note 20.1)	13,073,034,212	7,607,068,438	
Working capital loan (Note 20.2)	-	5,690,146	
	<b>13,073,034,212</b>	<b>7,612,758,584</b>	
Less: Current portion of long term loan (Note 20.3)	(201,882,832)	(256,375,584)	
	<b>12,871,151,380</b>	<b>7,356,383,000</b>	
<b>20.1 Syndicated loan and other long term loans</b>			
Agrani Bank Ltd. Principal. Br.	-	61,776,943	
Janata Bank Ltd	-	58,786,665	
Term Loan - AB Bank Ltd.	-	317,837,274	
Term Loan -Agrani Bank Ltd.	-	222,372,922	
Term Loan Premier Bank Ltd.	-	488,400,000	
Phoenix Finance & Investment Ltd.	188,353,872	224,410,610	
Bangladesh Finance and and Investment Ltd.	-	24,852,600	
Mashreq bank PSC	5,883,680,435	-	
Mercantile Bank Limited	-	750,000,000	
International leasing and financial services Ltd.	-	157,664,496	
Meridian finance & Investment Ltd.	13,356,974	22,697,487	
Agrani Bank Ltd. -BMRE	3,078,758,648	2,284,532,768	
Term Loan IPDC	-	510,798,096	
Social Islami Bank Ltd	938,069,748	845,565,953	
AL-Arafa Islami Bank Ltd.	1,776,578,444	1,596,609,845	
ODDO BHF AG Finance	576,109,548	40,762,780	
Rupali Bank Ltd.	618,126,543	-	
	<b>13,073,034,212</b>	<b>7,607,068,438</b>	
<b>Details have been presented in annexure- H</b>			
<b>20.2 Working capital loan</b>			
Agrani Bank Ltd. (CC Hypo)	-	5,690,146	
	<b>-</b>	<b>5,690,146</b>	
<b>20.3 Current portion of long term loan</b>			
International leasing and Financial Services Ltd.	-	157,664,496	
Meridian Finance & Investment Ltd.	12,119,184	12,119,184	
Phoenix Finance & Investment Ltd.	61,739,304	61,739,304	
Bangladesh Finance and and Investment Ltd.	-	24,852,600	
ODDO BHF AG Finance	128,024,344	-	
	<b>201,882,832</b>	<b>256,375,584</b>	

		Amount in Taka	
		30 June 2020	30 June 2019
<b>20.a Long term loan</b>			
International leasing and Financial Services Ltd.	-	157,664,496	
Meridian Finance & Investment Ltd.	13,356,974	22,697,487	
Phoenix Finance & Investment Ltd.	188,353,872	224,410,610	
Bangladesh Finance and and Investment Ltd.	-	24,852,600	
Agrani Bank Ltd. -BMRE	3,078,758,648	2,284,532,768	
Social Islami Bank Ltd	938,069,748	845,565,953	
AL-Arafa Islami Bank Ltd.	1,776,578,444	1,596,609,845	
ODDO BHF AG Finance	576,109,548	40,762,780	
Rupali Bank Ltd.	618,126,543	-	
	<b>7,189,353,777</b>	<b>5,197,096,539</b>	
Less: Current portion of long term loan (Note 20.a.1)	(201,882,832)	(256,375,584)	
	<b>6,987,470,945</b>	<b>4,940,720,955</b>	
<b>20.a.1 Current portion long term loan</b>			
International leasing and Financial Services Ltd.	-	157,664,496	
Meridian Finance & Investment Ltd.	12,119,184	12,119,184	
Phoenix Finance & Investment Ltd.	61,739,304	61,739,304	
Bangladesh Finance and and Investment Ltd.	-	24,852,600	
ODDO BHF AG Finance	128,024,344	-	
	<b>201,882,832</b>	<b>256,375,584</b>	
<b>21 Lease obligation</b>			
Phoenix Finance & Investment Ltd.	33,270,557	41,990,777	
Lease obligation (Office rent)	51,984,423	-	
	<b>85,254,980</b>	<b>41,990,777</b>	
Current portion of lease obligation (21.1)	(38,345,934)	(15,417,560)	
	<b>46,909,046</b>	<b>26,573,217</b>	
<b>21.1 Current portion of lease obligation</b>			
Phoenix Finance & Investment Ltd.	15,457,560	15,417,560	
Lease obligation (Office rent)	22,888,374	-	
	<b>38,345,934</b>	<b>15,417,560</b>	
<b>22 Employee benefits</b>			
Employee welfare fund (Note -22.1)	6,567,966	3,970,221	
Bangladesh workers welfare foundation (Note -22.2)	8,892,117	4,914,467	
Workers profit participation fund (Note -22.3)	36,404,155	17,002,094	
	<b>51,864,239</b>	<b>25,886,783</b>	
<b>22.1 Employee welfare fund</b>			
Opening balance	3,970,221	4,373,458	
Add: Addition for the year	3,977,650	1,346,698	
Less: Payment during the year	(1,379,905)	(1,749,934)	
	<b>6,567,966</b>	<b>3,970,221</b>	
<b>22.2 Bangladesh workers welfare foundation</b>			
Opening balance	4,914,467	3,567,769	
Add: Addition for the year	3,977,650	1,346,698	
	<b>8,892,117</b>	<b>4,914,467</b>	
<b>22.3 Workers profit participation fund</b>			
Opening balance	17,002,095	21,977,919	
Add: Addition for the year	31,821,206	10,773,581	
Less: Payment during the year	(12,419,146)	(15,749,406)	
	<b>36,404,155</b>	<b>17,002,094</b>	
<b>22.a Employee benefits</b>			
Employee welfare fund (Note -22.a.1)	3,854,428	3,970,221	
Bangladesh workers welfare foundation (Note -22.a.2)	6,178,579	4,914,467	
Workers profit participation fund (Note -22.a.3)	14,695,850	17,002,094	
	<b>24,728,858</b>	<b>25,886,783</b>	

Amount in Taka		
	30 June 2020	30 June 2019
<b>22.a.1 Employee welfare fund</b>		
Opening balance	3,970,221	4,373,458
Add: Addition for the year	1,264,113	1,346,698
Less: Payment during the year	(1,379,905)	(1,749,934)
	<b>3,854,428</b>	<b>3,970,221</b>
<b>22.a.2 Bangladesh workers welfare foundation</b>		
Opening balance	4,914,467	3,567,769
Add: Addition for the year	1,264,113	1,346,698
	<b>6,178,579</b>	<b>4,914,467</b>
<b>22.a.3 Workers profit participation fund</b>		
Opening balance	17,002,094	21,977,919
Add: Addition for the year	10,112,901	10,773,581
Less: Payment during the year	(12,419,146)	(15,749,406)
	<b>14,695,850</b>	<b>17,002,094</b>

WPPF is charged @ 5% of net profit before tax as per labour law Act 2006 (Amended in 2018 ), whereas 80% is allocated to "Workers profit participation fund", 10% to "Employee welfare fund" and 10% to "Bangladesh workers welfare foundation".

## 23 Deferred tax liability

Opening balance	98,226,477	78,995,050
Adjustment for deferred tax expenses /(income) (Note-23.1)	47,170,266	21,205,576
Adjustment for deferred tax on revaluation surplus (Note-23.2)	(2,785,671)	(1,974,149)
	<b>142,611,072</b>	<b>98,226,477</b>

## 23.1 Adjustment during the year on deferred tax on PPE

Deferred tax liability on PPE (closing)	92,896,578	45,726,312
Deferred tax liability on PPE (opening)	45,726,312	24,520,736
<b>Deferred tax expenses/(income)</b>	<b>47,170,266</b>	<b>21,205,576</b>

Particular	WDV as at 30 June 2020		Amount in Taka	
	Tax base	Accounting Base	Deferred tax liability as on 30.06.2020	Deferred tax liability as on 30.06.2019
Written down value of property, plant and equipment	3,504,988,302	3,876,574,612	(92,896,578)	(45,726,312)

## 23.2 Adjustment of deferred tax on revaluation Surplus

Deferred tax liability on revaluation surplus (Closing) (Note-23.2.1)	49,714,494	52,500,165
Deferred tax liability on revaluation surplus (Opening)	52,500,165	54,474,314
<b>Deferred tax expenses/(income)</b>	<b>(2,785,671)</b>	<b>(1,974,149)</b>

## 23.2.1 Adjustment of deferred tax on revaluation surplus

Particulars	WDV as at 30 June 2020		Amount in Taka	
	Tax Base	Accounting Base	Deferred Tax Liability as on 30.06.2020	Deferred Tax Liability as on 30.06.2019
Revaluation reserved on land & land development	-	1,298,728,729	(38,961,862)	(38,961,862)
Revaluation reserved factory & office building	-	67,682,516	(10,152,377)	(11,280,419)
Revaluation reserved plant & machinery	-	20,364,702	(3,054,705)	(3,593,771)
Revaluation reserve on marketable securities	-	(24,544,509)	2,454,451	1,335,888
<b>Total</b>	<b>-</b>	<b>1,362,231,438</b>	<b>(49,714,494)</b>	<b>(52,500,165)</b>

## 24. Shot term loans

Cash credit (Hypo) Agrani Bank Ltd., WASA Corp. Branch	357,913,873	357,815,415
LTR Agrani Bank Ltd., WASA Corporate Branch	142,200,919	141,075,571
Loan against marketable securities	65,880,930	66,392,478
	<b>565,995,722</b>	<b>565,283,464</b>

		Amount in Taka	
		30 June 2020	30 June 2019
<b>25 Trade and other payables</b>			
Goods suppliers & manufacturer	2,618,526,029	2,007,663,158	
Other payable	456,809,503	401,601,631	
Current account with inter companies (Note -25.1)	109,788,332	181,234,288	
	<b>3,185,123,864</b>	<b>2,590,499,077</b>	
<b>25.1 Current account with inter companies</b>			
Interior Accom Consortium Limited	33,157,000	33,157,000	
Orion Capital Ltd.	18,420,000	18,420,000	
Digital Power & Associates Ltd	-	54,095,379	
Orion Power Rupsha Ltd.	58,211,332	75,561,909	
	<b>109,788,332</b>	<b>181,234,288</b>	
These are unsecured and payable within Orion Power Rupsha Ltd.			
<b>25.a Trade and other payables</b>			
Goods suppliers & manufacturer	270,338,394	274,202,851	
Other payables	333,165,538	348,859,152	
	<b>603,503,932</b>	<b>623,062,003</b>	
<b>26. Accrued expenses</b>			
Salary and wages payable	81,647,029	85,781,615	
Director remuneration payable	10,649,877	8,925,000	
Depot expenses payable	300,000	-	
Telephone & mobile bill payable	1,042,140	1,190,355	
Payable for final settlement of employee	7,507,047	7,694,942	
Utilities payable	2,172,517	2,164,166	
Provision for income tax (Note 26.1)	197,862,877	188,622,950	
Corporate governance audit fees	57,500	57,500	
Statutory Audit fees	1,265,000	1,265,000	
Interest on preference share	-	155,243,639	
Retention money	3,618,657	3,618,657	
Retirement benefit- P.F.	34,048,932	32,506,296	
Provision for gratuity	21,622,489	16,997,422	
Interest payable on Phonix Finance and Investment Ltd.	2,279,198	3,746,272	
Interest payable on Mashreq Dubai	5,396,631	-	
Interest payable on term loan	5,692,894	129,101,742	
Withholding VAT	16,810,471	15,722,265	
Withholding tax	12,132,046	10,750,750	
	<b>404,105,305</b>	<b>663,388,571</b>	
<b>26.1 Provision for income tax</b>			
Opening balance	188,622,950	167,416,122	
Add: Addition during the year	17,777,911	44,244,820	
	<b>206,400,861</b>	<b>211,660,942</b>	
Less: Payment/AIT adjustment during the year	(8,537,984)	(23,037,992)	
	<b>197,862,877</b>	<b>188,622,950</b>	
<b>26.a Accrued expenses</b>			
Salary and wages payable	59,924,626	61,642,468	
Depot expenses payable	843,418	-	
Director remuneration payable	300,000	300,000	
Telephone & mobile bill payable	1,042,140	1,190,355	
Payable for final settlement of employee	7,507,047	7,694,942	
Utilities payable	2,172,517	2,164,166	
Provision for income tax (Note - 26.a.1)	197,862,877	188,622,950	
Corporate governance audit fees	57,500	57,500	
Statutory Audit fees	575,000	575,000	
	<b>270,285,125</b>	<b>262,247,380</b>	
These are unsecured & is payable within one year.			

		Amount in Taka	
		30 June 2020	30 June 2019
<b>26.a.1 Provision for income tax</b>			
Opening balance		188,622,950	167,416,122
Add: Addition during the year		17,777,911	44,244,820
		<b>206,400,861</b>	<b>211,660,942</b>
Less: Payment/AIT adjustment during the year		(8,537,984)	(23,037,992)
<b>Closing balance</b>		<b>197,862,877</b>	<b>188,622,950</b>
<b>27. Revenue from net sales</b>			
Local sales		2,144,549,213	2,048,430,562
Export sales		153,191,088	172,918,054
Gain/(loss) in exchange rate fluctuation		-	1,193,198
Revenue from power generation (Note-27.1)		5,349,962,730	6,482,631,053
		<b>7,647,703,031</b>	<b>8,705,172,867</b>
<b>27.1 Revenue from power generation</b>			
Reference rental price		2,645,760,000	2,617,280,770
Reference energy price (variable - O&M)		124,948,190	126,309,511
HFO received from OOSL		2,591,605,481	3,792,452,629
Foreign exchange gain /(loss)		(12,350,941)	(53,411,857)
		<b>5,349,962,730</b>	<b>6,482,631,053</b>
<b>27.a Revenue from net sales</b>			
Local sales		2,144,549,213	2,048,430,562
Export sales		153,191,088	172,918,054
Gain/(loss) on foreign exchange transaction		-	1,193,198
		<b>2,297,740,301</b>	<b>2,222,541,814</b>
<b>28. Cost of goods sold</b>			
Raw materials consumed (Note - 28.1)		440,014,412	423,581,407
Packing materials consumed (Note - 28.2 )		192,825,828	222,552,717
Work in process - opening		13,817,389	15,292,500
Work in process - closing		(17,129,910)	(13,817,389)
<b>Total consumption</b>		<b>629,527,720</b>	<b>647,609,236</b>
Factory overhead (Note - 28.3 )		431,014,446	314,316,780
<b>Cost of goods manufactured</b>		<b>1,060,542,166</b>	<b>961,926,016</b>
Add: Opening stock of finished goods		44,674,750	81,299,632
<b>Cost of goods available for sale</b>		<b>1,105,216,916</b>	<b>1,043,225,648</b>
Less: Closing stock of finished foods		(75,769,179)	(44,674,750)
Less: Cost of physician sample		(12,802,715)	(12,431,262)
<b>Cost of goods sold</b>		<b>1,016,645,021</b>	<b>986,119,636</b>
<b>28.1 Raw materials consumed</b>			
Opening stock		126,896,948	98,045,864
Add: Purchase during the year		458,543,800	452,432,491
Goods Available for use		585,440,748	550,478,355
Less: Closing stock		(145,426,337)	(126,896,948)
<b>Consumed during the year</b>		<b>440,014,412</b>	<b>423,581,407</b>
<b>28.2 Packing materials consumed</b>			
Opening stock		42,072,240	52,195,944
Add: Purchase during the year		218,981,273	212,429,013
Goods available for use		261,053,513	264,624,957
Less: Closing stock		(68,227,685)	(42,072,240)
<b>Consumed during the year</b>		<b>192,825,828</b>	<b>222,552,717</b>
<b>28.3 Factory overhead</b>			
Salaries, wages & other allowances		125,311,043	121,556,543
Travelling & conveyance		4,872,888	4,557,430
Entertainment		2,147,607	2,463,240
Worker's food expenses		15,282,708	15,697,794
Uniform, liveries & others		270,600	139,663
Godown rent		-	4,885,684
Utilities		33,176,712	17,470,605
Cleaning & washing		374,229	142,105
Carrying inward		601,648	633,814
Postage, telephone & others		466,816	524,808
Fuel & lubricants		4,954,266	4,211,017

		Amount in Taka	
		30 June 2020	30 June 2019
	Fees & taxes	1,305,658	721,022
	Books & periodicals	9,766	11,122
	Printing & stationery	5,553,745	5,154,464
	Insurance premium	1,542,832	1,258,835
	Repair & maintenance	8,486,255	8,286,711
	Depreciation (Annexure-A & B )	214,583,297	121,612,835
	Lease rent	185,896	557,688
	Research & development	751,419	1,150,636
	Spare parts	10,709,854	2,952,326
	Security services	427,208	328,438
		<b>431,014,446</b>	<b>314,316,780</b>
<b>29. Cost of power generation</b>			
	Opening balance	146,861,504	488,614,358
	Add: Purchase during the year (Note- 29.1)	2,913,764,434	3,686,042,366
		3,060,625,938	4,174,656,724
	Less: Closing balance	(187,202,025)	(146,861,504)
		2,873,423,913	4,027,795,220
	Add : Plant overhead (Note- 29.2)	1,179,796,154	1,145,574,574
		<b>4,053,220,067</b>	<b>5,173,369,794</b>
<b>29.1 Purchase of raw materials</b>			
	Mobil & chemical	67,877,520	72,650,059
	HFO - OOSL	2,845,886,914	3,613,392,307
		<b>2,913,764,434</b>	<b>3,686,042,366</b>
<b>29.2 Plant overhead</b>			
	O & M service	139,617,639	138,137,379
	Salaries & allowances	162,945,537	158,365,296
	Repair & maintenance	195,611,948	133,041,018
	Travelling & conveyance	7,979,688	5,645,309
	Insurance, taxes & duties	-	534,078
	Depreciation	621,497,454	649,918,337
	Miscellaneous expenses	44,920,447	33,176,245
	Foreign exchange gain/(loss)	-	20,226,454
	Land rent	6,912,684	6,530,458
	Insurance	310,756	-
		<b>1,179,796,154</b>	<b>1,145,574,574</b>
<b>30. General and administrative expenses</b>			
	Salaries, allowances & bonus	153,195,444	151,093,194
	Directors' remuneration	20,400,000	20,400,000
	Meeting attendance Fee	660,000	420,000
	Fuel & lubricants	4,214,239	3,442,341
	Travelling & conveyance	3,219,825	5,821,134
	Entertainment	3,806,802	4,826,888
	Office rent	-	9,527,186
	Cleaning & washing	4,962,427	4,734,006
	Utilities	19,539,843	12,639,931
	Postage, telephone & others	6,706,716	8,673,170
	Bank charges & commission	2,006,800	1,112,083
	Fees & taxes	21,138,920	10,724,285
	Fooding expenses	19,214,541	24,694,558
	Software consultancy & others	12,364,860	4,567,015
	Books & periodicals	99,501	103,730
	Printing & stationery	4,954,313	4,211,821
	Repair & maintenance	4,143,211	3,728,729
	Depreciation (Annexure-A & B )	70,697,807	37,305,787
	Lease rent	1,960,548	4,053,660
	Statutory audit fees	1,265,000	1,265,000
	Corporate governance audit fees	57,500	57,500
	Annual listing & other fees	1,200,000	1,200,000
	Overseas travel & training expenses	2,013,182	2,121,346
	Insurance premium	1,765,119	2,230,948
	Miscellaneous expenses	165,237	217,981
	AGM expenses	1,731,250	1,599,307
	Donation & Subscription	-	2,472,466
	Security services	13,566,936	16,010,221
	Advertisement & publicity	12,015,191	16,278,041
	Corporate social responsibility (CSR)	3,630,000	7,347,563

		Amount in Taka	
		30 June 2020	30 June 2019
		390,695,212	362,879,890
<b>30.a</b>	<b>General and administrative expenses</b>		
	Salaries, allowances & bonus	153,195,444	151,093,194
	Directors' remuneration	3,600,000	3,600,000
	Meeting attendance Fee	660,000	420,000
	Fuel & lubricants	4,214,239	3,442,341
	Travelling & conveyance	3,219,825	2,803,044
	Entertainment	2,042,845	2,343,082
	Office rent	-	9,527,186
	Cleaning & washing	4,962,427	4,734,006
	Utilities	18,236,512	11,562,846
	Postage, telephone & others	4,636,213	4,532,801
	Bank charges & commission	2,006,800	1,112,083
	Fees & taxes	3,401,503	4,296,118
	Fooding expenses	7,172,233	7,674,241
	Software consultancy & others	2,970,800	3,546,535
	Books & periodicals	99,501	103,730
	Printing & stationery	2,769,536	2,839,364
	Repair & maintenance	4,143,211	3,728,729
	Depreciation (Annexure-A & B )	70,697,807	37,305,787
	Lease rent	1,960,548	4,053,660
	Statutory audit fees	575,000	575,000
	Corporate governance audit fees	57,500	57,500
	Annual listing & other fees	1,200,000	1,200,000
	Overseas travel & training expenses	2,013,182	2,121,346
	Insurance premium	1,765,119	2,230,948
	Miscellaneous expenses	165,237	217,981
	AGM expenses	1,731,250	1,599,307
	Donation & Subscription	-	2,472,466
	Security services	1,425,657	1,169,858
	Advertisement & publicity	761,222	511,036
	Corporate social responsibility (CSR)	2,202,000	2,072,563
		<b>301,885,611</b>	<b>272,946,751</b>
<b>31.</b>	<b>Selling and distribution expenses</b>		
	Salaries, allowances & bonus	460,965,547	444,271,030
	Field force TA/DA	10,029,607	11,623,138
	Printing & stationery	8,031,732	8,145,528
	Postage, telephone & others	8,545,196	8,427,040
	Fooding expenses	1,298,230	1,497,410
	Product renewal & development	2,352,513	2,242,654
	Software consultancy & others	4,077,727	5,071,500
	Training & conference	5,329,855	5,738,564
	Office rent (Depot)	-	10,872,417
	Repair & maintenance	950,626	820,425
	Travelling & conveyance	1,388,899	1,239,154
	Bank charges & commission	1,787,025	2,215,289
	Carrying & distribution expenses	20,382,423	19,561,236
	Entertainment	1,047,613	1,201,581
	Promotional materials	14,187,914	15,164,175
	Sample expenses	12,802,715	12,431,262
	Export expenses	1,836,333	2,071,509
	Depreciation (Annexure-A & B )	30,037,244	13,226,408
	Lease rent	5,709,504	6,756,624
	Fuel & lubricants	2,167,511	2,124,311
	Fees & taxes	355,192	606,136
	Overseas travelling & training	965,815	661,535
	Security services	1,901,771	1,864,331
	Utilities	1,210,961	1,265,677
	Insurance premium	3,117,824	4,307,397
	Books & periodicals	10,451	9,836
	Advertisement & publicity	208,950	2,234,173
		<b>600,699,179</b>	<b>585,650,340</b>

		Amount in Taka	
		30 June 2020	30 June 2019
<b>32. Financial expense</b>			
Agrani Bank Limited, Cash Credit ( H ) - 48.	31,880,971	31,715,956	
Agrani Bank Limited, LTR	7,796,266	11,869,943	
Phoenix Finance & Investments Ltd.	35,532,879	28,936,193	
Internatiuonal Leasing and Financial	4,766,919	37,416,767	
Bangladesh Finance and and	18,403,237	3,763,579	
Meridian Finance & Investment Ltd.	2,788,424	4,081,633	
Agrani Bank Ltd	49,107,236	-	
Finance cost on lease obligation (Office rent)	4,222,401	-	
Interest on Long Term Borrowing	403,228,036	295,498,828	
Interest on redeemable Preference Share	159,286,324	121,725,998	
Interest Expense - Mashreq PSC	-	26,502,555	
Loan Processing fees	22,708,750	2,505,000	
Bank Charge ,commission & Fees	52,507,719	13,608,753	
	<b>792,229,161</b>	<b>577,625,205</b>	
<b>32a Financial expenses</b>			
Agrani Bank Limited, Cash Credit ( H ) - 48.	31,880,971	31,715,956	
Agrani Bank Limited, LTR	7,796,266	11,869,943	
Phoenix Finance & Investments Ltd.	35,173,637	28,420,436	
Internatiuonal Leasing and Financial	4,766,919	37,416,767	
Bangladesh Finance and and	18,403,237	3,763,579	
Meridian Finance & Investment Ltd.	2,788,424	4,081,633	
Agrani Bank Ltd	49,107,236	-	
Finance cost on lease obligation (Office rent)	4,222,401	-	
	<b>154,139,090</b>	<b>117,268,314</b>	
<b>33. Interest &amp; other income</b>			
Interest on FDR	1,076,613	724,053	
Interest income	31,702,573	25,521,918	
Dividend income	1,012,648	954,250	
Insurance claim received	199,286	568,289	
Sale of scrap & others	5,441,357	1,574,235	
Gain/(loss) on sale of marketable securities (Note 33.1)	(47,987)	(7,093,015)	
Gain / (loss) on foreign exchange fluctuations	1,707,763	-	
	<b>41,092,252</b>	<b>22,249,730</b>	
<b>33.1 Income on sale of marketable securities</b>			
Gain/(loss) on sale of marketable securities	(46,137)	527,646	
Interest on portfolio credit and others	(1,850)	(7,620,662)	
	<b>(47,987)</b>	<b>(7,093,015)</b>	
<b>34. Current tax</b>			
Profit before tax	252,822,527	269,339,528	
Add: Accounting depreciation	315,318,348	172,145,031	
Less: Tax depreciation	494,402,374	257,130,779	
Taxable income	<b>73,738,501</b>	<b>184,353,779</b>	
<b>Income tax provision</b>			
Particulars	Taxable income	Taxable amount	
		30 June 2020	30 June 2018
25% income tax on taxable profit	67,877,197	16,969,299	42,258,058
Half of 25% Income tax on export net profit	4,848,656	606,082	1,795,912
20% income tax on dividend received	1,012,648	202,530	190,850
<b>Total</b>	<b>73,738,501</b>	<b>17,777,911</b>	<b>44,244,820</b>
<b>Minimum tax</b>			
<b>Calculation of gross receipt</b>			
Revenue from net sales	2,297,740,301	2,222,541,814	
<b>Other income</b>			
Interest on FDR	1,076,613	724,053	
Interest Income	31,702,573	25,521,918	
Dividend income	1,012,648	954,250	
Insurance claim received	199,286	568,289	
Sale of scrap & others	5,441,357	1,574,235	
<b>Total Gross Receipts</b>	<b>2,337,172,778</b>	<b>2,251,884,559</b>	
<b>Minimum Tax (.60% On Total Gross Receipts)</b>	<b>14,023,037</b>	<b>13,511,307</b>	
<b>Tax provision whichever is higher</b>	<b>17,777,911</b>	<b>44,244,820</b>	

Income tax provision is higher between tax at regular rate on income and minimum tax on gross receipts U/S 82C 2(b) of IT Ordinance

		Amount in Taka	
		30 June 2020	30 June 2019
1984. Hence tax at regular rate is accounted for as it is higher than the minimum tax.			
<b>35 Earnings per share (EPS)</b>			
The computation is given below:			
Net profit after tax		665,686,161	882,354,974
Ordinary shares outstanding during the year		234,000,000	234,000,000
<b>Earning per share</b>		<b>2.84</b>	<b>3.77</b>
<b>35a Earnings per share</b>			
The computation is given below:			
Net profit after tax		194,342,150	212,611,542
Ordinary shares outstanding during the year		234,000,000	234,000,000
<b>Earnings per share</b>		<b>0.83</b>	<b>0.91</b>
During the reporting year the company did not issue any share. Hence there is no required to calculate weighted average ordinary share.			
<b>36. Clause No. 5 (2) (e) of Notification No. BSEC/CMRRCD/2006-158/208/Admin/81, Dated: 20 June 2018: Reconciliation of Net operating cash flow under Indirect Method:</b>			
Particulars	30-Jun-20	30-Jun-19	
Net profit before tax	795,530,136	1,028,310,759	
Workers profit participation fund	12,641,126	13,466,976	
Interest & other income	(41,092,253)	(22,249,730)	
Financial expenses	792,229,161	577,625,205	
Depreciation	936,815,801	822,063,368	
Increase/(Decrease) in inventory	(359,569,078)	270,460,857	
Increase/(Decrease) in receivables	(978,163,862)	200,335,402	
Increase/(Decrease) in advance deposit & prepayments	(340,650,714)	(31,588,748)	
Increase/(Decrease) in employee benefit	13,336,330	(17,499,340)	
Increase/(Decrease) in payable	1,010,201,355	(1,389,674,380)	
Increase/(Decrease) in accrued expenses	77,101,224	24,822,898	
Income taxes paid	(36,465,342)	(47,752,252)	
Foreign exchange gain/(loss)	417,728	20,226,454	
<b>Net cash flow from operating Activities</b>	<b>1,882,331,611</b>	<b>1,448,547,470</b>	
<b>36.1 Net operating cash flow per share</b>	<b>8.04</b>	<b>6.19</b>	
<b>36a Clause No. 5 (2) (e) of Notification No. BSEC/CMRRCD/2006-158/208/Admin/81, Dated: 20 June 2018: Reconciliation of Net operating cash flow under Indirect Method:</b>			
Particulars	30-Jun-20	30-Jun-19	
Net profit before tax	252,822,527	269,339,528	
Workers profit participation fund	12,641,126	13,466,976	
Interest & other income	(41,092,253)	(22,249,730)	
Financial expenses	154,139,090	117,268,314	
Depreciation	315,318,348	172,145,031	
Increase/(Decrease) in inventory	(74,583,107)	1,337,938	
Increase/(Decrease) in receivables	14,518,514	(28,264,050)	
Increase/(Decrease) in advance, deposit & prepayments	824,947	14,696,665	
Increase/(Decrease) in employee benefit	(13,799,051)	(17,499,340)	
Increase/(Decrease) in payable	2,501,495	101,863,089	
Increase/(Decrease) in accrued expenses	(1,202,183)	9,139,098	
Income taxes paid	(36,465,342)	(47,752,252)	
Foreign Exchange Gain/(Loss)	417,728	-	
<b>Net cash flow from operating activities</b>	<b>586,041,838</b>	<b>583,491,267</b>	
<b>36a.1 Net operating cash flow per share</b>	<b>2.50</b>	<b>2.49</b>	

### 37. Segmental information

The Group's operational segments are pharmaceuticals, power, and investments. The operational segments results are as follows:

Particulars	Pharmaceuticals	Power	Totals
Revenue from sales	2,297,740,301	5,349,962,730	7,647,703,031
Expenses	(1,919,229,811)	(4,142,029,668)	(6,061,259,480)
<b>Segment result</b>	<b>378,510,490</b>	<b>1,207,933,062</b>	<b>1,586,443,551</b>
<b>Capital expenditure</b>			
Additions to property, plant & equipment	2,903,212,570	1,074,234	2,904,286,804
<b>Other segment information</b>			
Interest & other income	41,092,252	-	41,092,252
Financial Expenses	(154,139,090)	(638,090,071)	(792,229,161)
Provision for income tax	(17,777,911)	-	(17,777,911)
Share of profit from associate	6,467,800	-	6,467,800
Depreciation expenses	(315,318,348)	(621,497,454)	(936,815,802)
<b>Segment assets</b>	<b>19,862,455,800</b>	<b>16,978,650,965</b>	<b>36,841,106,765</b>
<b>Segment liabilities</b>	<b>8,881,733,465</b>	<b>8,769,661,491</b>	<b>17,651,394,956</b>

### 38. Related party transactions

38.1 The Company has entered into transactions with other entities that fall within the definition of related party as contained in IAS-24 "Related Party Disclosures". The Company opines that terms of related party transactions do not significantly differ from those that could have been obtained from third parties. Total transactions of the significant related parties as at 30 June 2020 are as follows:

Name of Related Party	Relationship	Nature of Transaction	Opening Balance as on 01.07.2019	Addition during the year	Adjustment during the year	Closing Balance as on 30.06.2020
Orion Power Meghnaghat Ltd. (95,000,000 Ordinary Shares @ TK 10 Each)	Subsidiary	Investment in Shares	950,000,000	-	-	950,000,000
Dutch Bangla Power & Associates Ltd. (6,700,000 Ordinary Shares @ Tk. 10 Each)	Subsidiary	Investment in Shares	67,000,000	-	-	67,000,000
Orion Infusion Ltd. (44,30,000 Ordinary Shares @ TK. 10 each)	Associate	Investment in Shares	44,300,000	-	-	44,300,000
Orion Power Khulna Ltd. (50,000 Ordinary Shares @ TK. 10 each)	Trade Investment	Investment in Shares	500,000	-	-	500,000
Orion Power Dhaka Ltd. (50,000 Ordinary Shares @ TK. 10 each)	Trade Investment	Investment in Shares	500,000	-	-	500,000
Orion Infrastructure Ltd. (200,000,000 Ordinary Shares @ TK. 10 each)	Trade Investment	Investment in Shares	2,117,209,676	-	-	2,117,209,676
Orion Infusion Ltd.	Associate	Receivable / (Payable)	(63,728,273)	-	-	(63,728,273)
Dutch Bangla Power & Associate Ltd.	Subsidiary	Inter Company Current A/C	370,748,526		(1,348,762)	369,399,764
Orion Properties Ltd.	Common Director/ Shareholders	Inter Company Current A/C	20,331,532	-		20,331,532
Orion Power Khulna Ltd.	Trade Investment	Inter Company Current A/C	986,021,913	-	-	986,021,913
Orion Power Dhaka Ltd.	Trade Investment	Inter Company Current A/C	2,176,293,707	-	-	2,176,293,707
Orion Agro Product Ltd.	Common Director/ Shareholders	Inter Company Current A/C	232,265,920	-	-	232,265,920
Interior Accom Consortium Ltd.	Common Director/ Shareholders	Inter Company Current A/C	107,995,459	-	-	107,995,459
Orion Power Unit -2 Dhaka Ltd.	Common Director/ Shareholders	Inter Company Current A/C	1,483,046,176	-	(124,337,400)	1,358,708,776
Orion Power Rupsha Ltd.	Inter Company	Inter Company Current A/C	186,800,000	-		186,800,000
Digital Power & Associates Ltd.	Inter Company	Inter Company Current A/C	97,341,915	-	-	97,341,915
Orion Hospitals Ltd.	Inter Company	Inter Company Current A/C	2,000,000	10,700,000	-	12,700,000
Kohinoor Chemical Co. (BD) Ltd.	Inter Company	Trading Goods	(3,224,963)	894,825	(2,302,096)	(4,632,234)
<b>Total:</b>			<b>8,775,401,588</b>	<b>11,594,825</b>	<b>(127,988,258)</b>	<b>8,659,008,155</b>

\* All related party transaction have complied with the BSEC (notification no. BSEC/CMRRCD/ 2009-193/Admin / 103 dated February 5, 2020) during the financial year.

### 38.2 Payments/ Perquisites to Key Management Personnel

Payments and perquisites given to the Board of Directors, Company Secretary, Chief Financial Officer, Head of Internal Audit, Vice Presidents, Assistant Vice Presidents during the year are disclosed below:

Particulars	Amount in Taka	
	30 June 2020	30 June 2019
Basic salary	14,877,228	13,120,568
House rent	7,488,632	6,561,757
Medical allowance	1,254,000	857,467
Conveyance	1,071,000	748,033
Other allowance	2,917,563	3,225,034
Bonus	1,441,363	1,654,744
Profit participation fund	1,155,344	645,300
Contribution to provident fund (employer)	1,319,058	912,774
LFA	-	455,886
	<b>31,524,188</b>	<b>28,181,563</b>

During the year no board meeting attendance fee was paid to the directors.

**39. Production capacity**

Item	Unit	Production Capacity		Yearly Production		Capacity Utilization	
		2020	2019	2020	2019	2020	2019
Tablet & capsule	Million Pcs	1,420.50	694.26	523.20	508.57	36.83%	73.25%
Oral liquid, injection, powder for suspension, cream & ointment	Million Pcs	30.45	23.68	17.27	15.49	56.72%	65.42%

**40. General****40.1 Capital expenditure commitment**

There was capital expenditure contracted but not incurred or provided as on 30 June 2020 and material capital expenditure authorized by the board.

**40.2 Claims not acknowledged**

There is no claim against the company not acknowledged as debt as on 30 June 2020

**40.3 Credit facilities not availed**

There is no credit facilities available to the company as on 30 June 2020 under any contract, other than trade credit available in the ordinary course of business.

**40.4 Director's responsibility statements**

The Board of Directors take the responsibility for the preparation and presentation of these financial statements.

**40.5 Commission, brokerage or discount agents sales:**

No commission, brokerage or discount was incurred or paid by the company against sales during the period from 1 July 2019 to 30 June 2020.

**40.6 Employee details**

i) During the year, there were 2,244 employees employed for the full year and 452 employees less than the full year at a remuneration of Taka 3,000 per month and above.

ii) At the end of the period, there were 2,696 employees in the Company.

**40.7 Rounding off**

Amounts appearing in these financial statements have been rounded off to the nearest Taka and, wherever considered necessary.

**41. Events after the reporting period**

**41.1** The Board of Directors meeting held on 08 November 2020 had recommended 10% cash dividend for the year ended 30 June 2020 for placement before the Shareholder's for approval at 55<sup>th</sup> AGM of the company. There is no material events after the reporting date that are not adjusting events came to management attention which may be needful for the stakeholders.

**41.2** Except the facts above, there was no material event after the reporting date that is adjusting/ non adjusting event came to management attention which may be needful to be disclosed for the stakeholders.

**Managing Director**

**Director**

**Chief Financial Officer**

**Company Secretary**

Dated, Dhaka;  
08 November 2020

**ORION PHARMA LIMITED AND ITS SUBSIDIARIES**  
**SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT**  
**As at 30 June 2020**

**Annexure-A. 1**

Amount in Taka

Particulars	Written down value as at 01.07.2019	Additions during the year	Sale /Disposal During the year	Total as on 30.06.2019	Rate of Dep.(%)	Depreciation charged during the year	Written down value as at 30.06.2020
Land & land development	2,721,799,335	127,957,031	-	2,849,756,366	-	-	2,849,756,366
Factory & office building	484,657,538	1,899,698,457		2,384,355,995	10%	114,185,704	2,270,170,292
Plant & machinery	7,499,276,746	249,755,124		7,749,031,870	15%	708,653,084	7,040,378,787
Furniture & fixtures	75,008,991	9,910,291	-	84,919,282	15%	12,201,730	72,717,552
Office equipment	102,220,557	16,115,555		118,336,112	15%	17,826,737	100,509,375
Vehicles	21,091,188	12,619,453	(1,517,015)	32,193,626	20%	4,585,846	27,607,780
Laboratory equipment	51,305,515	-		51,305,515	15%	7,695,828	43,609,687
Road & Road Development		588,230,892		588,230,892	2%	2,941,154	585,289,738
<b>Sub-total:</b>	<b>10,955,359,870</b>	<b>2,904,286,804</b>	<b>(1,517,015)</b>	<b>13,858,129,659</b>		<b>868,090,083</b>	<b>12,990,039,576</b>

**At Revaluation**

Land & land development	1,599,675,401	-		1,599,675,401		-	1,599,675,401
Factory & office building	90,163,874	-		90,163,874	10%	8,719,646	81,444,228
Plant & machinery	230,138,177	-	-	230,138,177	15%	20,108,556	210,029,621
<b>Sub-total:</b>	<b>1,919,977,451</b>	<b>-</b>	<b>-</b>	<b>1,919,977,452</b>		<b>28,828,201</b>	<b>1,891,149,250</b>

<b>Leased Assets</b>							
Vehicle	62,191,763	-	-	62,191,763	20%	12,438,353	49,753,410
<b>Sub-total:</b>	<b>62,191,763</b>	<b>-</b>	<b>-</b>	<b>62,191,763</b>		<b>12,438,353</b>	<b>49,753,410</b>

<b>Total 2019-2020</b>	<b>12,937,529,084</b>	<b>2,904,286,804</b>	<b>(1,517,015)</b>	<b>15,840,298,874</b>	<b>-</b>	<b>909,356,636</b>	<b>14,930,942,237</b>
------------------------	-----------------------	----------------------	--------------------	-----------------------	----------	--------------------	-----------------------

<b>Total 2018-2019</b>	<b>13,144,226,580</b>	<b>616,465,384</b>	<b>(1,099,512)</b>	<b>13,759,592,452</b>	<b>-</b>	<b>822,063,368</b>	<b>12,937,529,084</b>
------------------------	-----------------------	--------------------	--------------------	-----------------------	----------	--------------------	-----------------------

**ORION PHARMA LIMITED**  
**Schedule of property, plant and equipment**  
**As at 30 June 2020**

**Annexure-A.2**

Amount in Taka

SL. No.	Particulars	Written down value as at 01.07.2019	Addition during the year	Disposal/sale during the year	Balance as on 30.06.2020	Rate of Dep. (%)	Depreciation charged during the year	Written down value as at 30.06.2020
1	Land & land development	2,469,265,069	127,957,031	-	2,597,222,100	-	-	2,597,222,100
2	Factory & office Building	150,344,478	1,899,698,457	-	2,050,042,935	10%	62,526,909	1,987,516,026
3	Plant & machinery	927,667,521	249,755,124	-	1,177,422,646	15%	159,499,913	1,017,922,733
4	Furniture & fixtures	75,008,992	9,910,291	-	84,919,283	15%	12,201,731	72,717,552
5	Office equipment	97,920,020	15,041,321	-	112,961,341	15%	15,844,936	97,116,405
6	Vehicles	15,142,934	12,619,453	(1,517,015)	26,245,372	20%	3,596,308	22,649,064
7	Laboratory equipment	51,305,514	-	-	51,305,514	15%	7,695,827	43,609,687
8	Road & Road Development	-	588,230,892	-	588,230,892	2%	2,941,154	585,289,738
	<b>A. Sub-Total</b>	<b>3,786,654,527</b>	<b>2,903,212,570</b>	<b>(1,517,015)</b>	<b>6,688,350,082</b>		<b>264,306,779</b>	<b>6,424,043,303</b>

**At revaluation**

1	Land & land development	1,298,728,729		-	1,298,728,729	-	-	1,298,728,729
2	Factory & office building	75,202,796		-	75,202,796	10%	7,520,280	67,682,516
3	Plant & machinery	23,958,473		-	23,958,473	15%	3,593,771	20,364,702
	<b>B. Sub-Total</b>	<b>1,397,889,997</b>	<b>-</b>	<b>-</b>	<b>1,397,889,997</b>		<b>11,114,051</b>	<b>1,386,775,947</b>

**Leased asset**

1	Vehicles	62,191,762	-		62,191,762	20%	12,438,352	49,753,409
	<b>Sub-total:</b>	<b>62,191,762</b>	<b>-</b>	<b>-</b>	<b>62,191,762</b>		<b>12,438,352</b>	<b>49,753,409</b>
<b>TOTAL (A+B+C)-2019-2020</b>		<b>5,246,736,287</b>	<b>2,903,212,570</b>	<b>(1,517,015)</b>	<b>8,148,431,841</b>	<b>-</b>	<b>287,859,182</b>	<b>7,860,572,660</b>
<b>TOTAL - 2018-2019</b>		<b>4,809,521,233</b>	<b>610,459,597</b>	<b>(1,099,512)</b>	<b>5,418,881,318</b>	<b>-</b>	<b>172,145,031</b>	<b>5,246,736,287</b>

Allocation of depreciation charge for the year has been made in the accounts as follows:

SL. No.	Particulars	Factory overhead	General and admin expense	Selling & distribution expense	Total
1	Factory & office Building	28,018,876	35,023,594	7,004,719	70,047,189
2	Plant & machinery	163,093,684	-	-	163,093,684
3	Furniture & fixtures	2,440,346	4,880,692	4,880,692	12,201,731
4	Office equipment	3,168,987	8,714,715	3,961,234	15,844,936
5	Vehicles	359,631	2,517,416	719,262	3,596,308
6	Lease -vehicle	-	9,950,682	2,487,670	12,438,352
7	Laboratory equipment	7,695,827	-	-	7,695,827
8	Road & Road Development	2,941,154	-	-	2,941,154
	<b>Total</b>	<b>207,718,505</b>	<b>61,087,099</b>	<b>19,053,577</b>	<b>287,859,182</b>

# ORION PHARMA LIMITED

## Schedule of Right of Use Assets

As at 30 June 2020

**Annexure-B**

**Amount in Taka**

SL. No.	Particulars	Written down value as at 01.07.2019	Addition during the year	Balance as on 30.06.2020	Rate of Depreciation	Depreciation charged during the year	Written down value as at 30.06.2020
1	Right of use Assets	-	77,807,019	77,807,019	-	27,459,166	50,347,853
	<b>Total</b>	<b>-</b>	<b>77,807,019</b>	<b>77,807,019</b>	<b>-</b>	<b>27,459,166</b>	<b>50,347,853</b>

Allocation of depreciation charge for the year has been made in the accounts as follows:

Particulars	Factory overhead	General & administration expense	Selling & distribution expense	Total
1 Right of use Assets	6,864,792	9,610,708	10,983,666	27,459,166
<b>Total</b>	<b>6,864,792</b>	<b>9,610,708</b>	<b>10,983,666</b>	<b>27,459,166</b>

**ORION PHARMA LIMITED**  
**Investment in Marketable Securities**  
**For the year ended 30 June 2020**

**Annexure-C**

**Amount in Taka**

Particulars	30-Jun-20		30-Jun-19	
	Market Value	Cost Price	Market Value	Cost Price
<b>AB Investment Ltd.</b>				
Alif Industries Ltd.	1,262,063	4,554,183	2,768,669	4,554,183
Apex Footwear Ltd.	10,862,368	18,755,421	14,656,519	18,755,421
Central Pharmaceuticals Ltd.	79,933	161,317	75,726	161,317
Islami Bank Bangladesh Ltd.	1,741,828	3,484,013	2,348,979	3,484,013
<b>Sub- total</b>	<b>13,946,191</b>	<b>26,954,934</b>	<b>19,849,892</b>	<b>26,954,934</b>
<b>Bank Asia Securities Ltd</b>				
Intech Online Ltd.	1,007,303	2,778,306	1,665,133	2,778,306
Islami Bank Bangladesh Ltd.	525,000	1,334,853	708,000	1,334,853
Summit Alliance Port Ltd.	690,560	2,074,176	956,000	2,074,000
Golden Harvest Agro Industries Ltd.	-	-	103,796	130,407
Agni Systems Ltd.	738,675	1,364,895	1,113,525	1,364,895
National Housing Finance & Investment Ltd.	270,600	622,270	468,600	622,270
Premier Leasing & Finance Ltd.	540,225	1,891,890	1,003,275	1,891,890
<b>Sub- total</b>	<b>3,772,363</b>	<b>10,066,390</b>	<b>6,018,329</b>	<b>10,196,621</b>
<b>LankaBangla Securities Ltd.</b>				
Intech Online Ltd.	588,000	1,193,140	972,000	1,193,140
Legacy Footwear Ltd.	817,700	1,733,821	1,732,900	1,733,821
National Housing Ltd.	1,623,600	2,836,434	2,811,600	2,836,434
The ACME Laboratories Ltd.	3,168,732	5,676,375	3,850,000	5,678,647
<b>Sub- total</b>	<b>6,198,032</b>	<b>11,439,770</b>	<b>9,366,500</b>	<b>11,442,042</b>
<b>Grand Total</b>	<b>23,916,586</b>	<b>48,461,094</b>	<b>35,234,721</b>	<b>48,593,597</b>

<b>Fair value adjustments</b>	<b>2019-2020</b>	<b>2018-2019</b>
Cost Price	48,461,094	48,593,597
Market Price	23,916,586	35,234,721
<b>Unrealized gain / (Loss)</b>	<b>(24,544,509)</b>	<b>(13,358,876)</b>

**ORION PHARMA LIMITED**  
**Fixed deposit with banks**  
**As at 30 June 2020**

**Annexure-D**

Amount in Taka

Sl. No.	Name of Bank	Instrument no.	Opening balance 01.07.2019	Re-Invested amount	Interest income					Closing balance 30.06.2020
					Accrued during the year	Accrued previous year	Realized during the year	Income during the year	Tax at source	
1	Social Islami Bank Ltd.-MTDR	0025311263757	1,725,015	1,832,217	5,191	5,463	119,114	118,843	11,911	1,832,217
2	Social Islami Bank Ltd.-MTDR	0025311260179	2,660,608	2,819,694	16,448	17,294	176,762	175,916	17,676	2,819,694
3	Social Islami Bank Ltd.-MTDR	0025311255512	3,642,713	3,860,524	46,326	43,105	242,012	245,233	24,201	3,860,524
<b>Sub total</b>			<b>8,028,336</b>	<b>8,512,435</b>	<b>67,966</b>	<b>65,862</b>	<b>537,888</b>	<b>539,992</b>	<b>53,789</b>	<b>8,512,435</b>
4	Agrani Bank Ltd. - FDR	0200012681578	1,500,000	1,622,173	14,769	59,250	135,748	91,266	13,575	1,622,173
5	Agrani Bank Ltd. - FDR	0200012311958	2,500,000	2,732,754	28,808	135,764	258,615	151,659	25,862	2,732,754
6	Agrani Bank Ltd. - FDR	0200014640505	-	3,078,127	9,833	-	86,808	96,641	8,681	3,078,127
7	Agrani Bank Ltd. - FDR	0200013746245	-	3,637,609	44,157	-	152,899	197,055	15,290	3,637,609
<b>Sub total</b>			<b>4,000,000</b>	<b>11,070,663</b>	<b>97,566</b>	<b>195,014</b>	<b>634,070</b>	<b>536,621</b>	<b>63,407</b>	<b>11,070,663</b>
<b>Total</b>			<b>12,028,336</b>	<b>19,583,098</b>	<b>165,532</b>	<b>260,876</b>	<b>1,171,958</b>	<b>1,076,613</b>	<b>117,196</b>	<b>19,583,098</b>

**ORION PHARMA LIMITED**  
**Balance with Banks on Account**  
**As at 30 June 2020**

**Annexure - E**

**Amount in Taka**

Sl. No.	Name of Bank	Name of Branch	Account Number	30 June 2020	30 June 2019
<b>Current Accounts (Main)</b>					
1	Pubali Bank Ltd.	Tejgaon Branch, Dhaka	1256	425	1,575
2	Sonali Bank Ltd.	Tejgaon Branch, Dhaka	275/4	47,201	47,201
3	Agrani Bank Ltd.	Wasa Branch, Dhaka	797310	879,253	3,126,509
4	Rupali Bank Ltd.	TCB Branch, Dhaka	708	21,547	21,547
5	National Bank Ltd.	Mohakhali Branch	34017	76,178	2,775,435
6	ICB Islami Bank Ltd.	Principal Office, Dhaka	6417	2,896,062	2,898,792
7	The City Bank Ltd.	Principal Branch, Dhaka	110558491	5,000	5,000
8	The City Bank Ltd.	Gulshan Branch, Dhaka	11001	4,945	5,290
9	Social Islami Bank Ltd.	Principal Branch, Dhaka	55830	694,020	2,732,199
10	Bank Al-Falah Ltd.	Motijheel Branch, Dhaka	2965	8,500	8,500
11	Agrani Bank Ltd.	Principal Branch, Dhaka	3884	559,830	561,020
12	Sonali Bank Ltd.	Farmgate Branch	33010919	137,206	270,267
13	AB Bank Ltd	Principal Branch	4005-784715-000	792,513	33,434
14	The Premier Bank Ltd	Gulshan Branch	5448	93,780	94,470
15	Brac Bank Ltd	Gulshan Branch	250001	617,897	608,261
16	AL-Arafa Islami Bank Ltd.	Corporate Branch, Dhaka	50228	25,405	29,555
17	Agrani Bank Ltd.	Shiddirgonj Branch	5002	22,407	-
18	Rupali Bank Ltd.	Local office Branch	262	100,632	-
<b>Sub Total (i)</b>				<b>6,982,801</b>	<b>13,219,055</b>
<b>Current Accounts (Collection)</b>					
19	Agrani Bank Ltd.	Chattogram Branch,	363	15,979	15,979
20	Agrani Bank Ltd.	Bogura Branch, Bogura	1233	11,659	11,659
21	Agrani Bank Ltd.	Rupsha Stand Road, Khulna	6069	1,667,528	21,046
22	Agrani Bank Ltd.	Barishal Branch, Barishal	1804	318	318
23	Agrani Bank Ltd.	Sylhet Branch, Sylhet	1866/1314	7,303	7,303
24	Agrani Bank Ltd.	Court Road Br. Narayangong	6467	484,003	91,563
25	Agrani Bank Ltd.	Rangpur Branch, Rangpur	4405	68	68
26	Agrani Bank Ltd.	Monoharpur Br. Cumilla	5304	70	70
27	Agrani Bank Ltd.	Faridpur Branch, Faridpur	4008	95,004	2,344
28	National Bank Ltd.	Bogura Branch, Bogura	1565	89,488	9,263
29	National Bank Ltd.	Barishal Branch, Barishal	0382	667,824	644,308
30	National Bank Ltd.	Subid Bazar Branch, Sylhet	7190	493,424	315,754
31	National Bank Ltd.	Mymensingh Branch	2957	450,243	8,290
32	National Bank Ltd.	Rangpur Branch, Rangpur	6653	468,455	37,593
33	National Bank Ltd.	Babu Bazar Branch, Dhaka	2378	19,016	19,016
34	Sonali Bank Ltd.	Greter Road Br. Rajshahi	1432	749,065	5,758
35	Agrani Bank Ltd.	Chowmohani Branch	9074	846,307	118,863
36	ICB Islami Bank Ltd.	Chattogram Branch,	2978	13,744	13,744
37	National Bank Ltd.	Gonestala Road, Dinajpur	3678	726,755	401,913
38	National Bank Ltd.	Tangail	2605	500,140	23,891
39	National Bank Ltd.	Moulavibazar	7153	1,077,584	461,367

**ORION PHARMA LIMITED**  
**Balance with Banks on Account**  
**As at 30 June 2020**

**Annexure - E**

**Amount in Taka**

<b>Sl. No.</b>	<b>Name of Bank</b>	<b>Name of Branch</b>	<b>Account Number</b>	<b>30 June 2020</b>	<b>30 June 2019</b>
40	Agrani Bank Ltd.	New Market Br.Kustia	8152	31,270	155,118
41	National Bank Ltd.	Cox's Bazar	13962	8,518	3,021
42	Agrani Bank Ltd.	BSCIC Cumilla	6639	122	2,858
43	National Bank Ltd.	CDA, Chattogram	6171	830,311	207,000
44	National Bank Ltd.	Sikder Tower Branch Sylhet	9870	28,295	29,215
45	Agrani Bank Ltd.	Wasa Corp. Br	Fund Buildup	2,879,993	-
<b>Sub Total (ii)</b>				<b>12,162,486</b>	<b>2,607,322</b>
<b>Sub Total (i+ii )</b>				<b>19,145,287</b>	<b>15,826,377</b>
<b>STD Accounts</b>					
46	National Bank Ltd.	Mohakhali	2515	31,745	1,766,948
47	Bank Asia Ltd.	Mohakhali	00038	151,749	86,142
48	Agrani Bank Ltd.	WASA Branch	99023	598,360,488	3,736,958
49	Social Islmi Bnk Ltd.	Principal Branch	1464	407,666	5,566
50	AB Bank Ltd.	Principal Branch	784715-000	130,960	129,194
51	Bank Asia Ltd.	Mohakhali	000190	64,852	129,881
52	AB Bank Ltd.	Principal Branch	760188-430	103,056	72,517
53	Agrani Bank Ltd.	Wasa Corp. Br	200014863618	3,423,698	-
<b>Sub Total (iii)</b>				<b>602,674,214</b>	<b>5,927,206</b>
<b>Total Balance in current &amp; STD accounts (i+ii+iii)</b>				<b>621,819,501</b>	<b>21,753,583</b>

**ORION PHARMA LIMITED AND ITS SUBSIDIARIES**  
**Redeemable Preference Share**  
**As at 30 June 2020**

**Annexure - F**

	<b>Amount in Taka</b>	
	<b>30 June 2020</b>	<b>30 June 2019</b>
Dutch Bangla Power & Associates Limited	-	500,000,000
	<b>-</b>	<b>500,000,000</b>

The redeemable preference shares bearing interest @ 15% per annum were issued by Agrani Bank. As per IFRS 7-"Financial Instrument: Disclosure" the substance of a financial instrument rather than its legal form governs its classification on the entity's financial statements. Accordingly, the redeemable preference shares which, in substance, meet the conditions of a financial liability, have been classified as liabilities in the financial statements.

**ORION PHARMA LIMITED AND ITS SUBSIDIARIES**  
**Provision for Decommissioning of Assets**  
**As at 30 June 2020**

**Annexure - G**

	<b>Amount in Taka</b>	
	<b>30 June 2020</b>	<b>30 June 2019</b>
Plant & machinery	59,922,594	59,922,594
Building	83,482,969	83,482,969
	<b>143,405,563</b>	<b>143,405,563</b>

Orion Power Megnaghat Ltd. has established its electricity generating plant on government land and assumed that after the contract period it may have to be removed from the land. The company has recognized a provision for decommission obligations associated the electricity generating facility. In determining the fair value of the provision, assumptions and estimates are made in relation to discount rates, the expected cost to dismantle and remove the plant from the site and the expected timing of those costs. The carrying amount of the provision as at 30 June , 2020 was BDT 143,405,563.

# ORION PHARMA LIMITED AND ITS SUBSIDIARIES

## Term Loan As at 30 June 2020

**Annexure -H**

### Orion Power Meghnaghat Ltd.

Term loan -Mashreq bank-PSC Dubai

Amount in Taka	
30 June 2020	30 June 2019
2,941,840,217	-
<b>2,941,840,217</b>	<b>-</b>

### Dutch Bangla Power and Associates Ltd.

Syndication loan

Term loan -Mashreq bank-PSC Dubai

Working capital loan

-	2,409,971,899
2,941,840,217	-
-	5,690,146
<b>2,941,840,217</b>	<b>2,415,662,045</b>

### Syndication loan

#### Long term borrowings

Agrani Bank Limited - Principal Branch

Janata Bank Limited

Term Loan - AB Bank Limited.

Term Loan - Agrani Bank Limited.

Term Loan -Premier Bank Limited.

Term Loan IPDC

Mercantile Bank Ltd.

-	61,776,943
-	58,786,665
-	317,837,274
-	222,372,922
-	488,400,000
-	510,798,096
-	750,000,000
<b>-</b>	<b>2,409,971,899</b>

The loans from banks are secured first ranking fixed charge over land, buildings and civil constructions, plant & machineries of the company, a first ranking floating charge over the stocks, receivables, revenue/sale proceeds, proceeds of accounts, insurance proceeds in favour of the term loan lenders on pari passu and pro rata basis. The company has also assigned benefits under all insurance policies on pari passu basis to the lenders.

The loans are also secured by personal guarantee of all directors of the company and lien of initial paid up capital of the promoters of the company.

The sponsors have also given an undertaking to retain the majority share of the project during the tenor of the loan, to be in control of the management of the company and to inject necessary equity fund to finance any cost overrun of the project and to maintain all the covenants unless otherwise mutually agreed between the lenders and the company.

### Working capital loan

Agrani Bank Limited- Principal Branch

-	5,690,146
<b>-</b>	<b>5,690,146</b>

Working capital loan under syndication loan arrangement bearing interest @ 9.00% per annum are repayable in 23 equal monthly installments starting from 09 September 2018.